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1. INTRODUCTION 
 
1.1 Endothelial barrier function  
Vascular endothelium lining the intima of blood vessels acts as a gatekeeper and 
actively controls the exchange /trafficking of water, small solutes, ions, blood cells and 
macromolecules across the vessel wall (Michel and curry, 1999; Mehta et al., 2004; 
Rao et al., 2005; Mehta and Malik, 2006). Failure of this endothelial cell (EC) barrier 
function results in an increased EC permeability, leakage of blood components and 
exudation of fluids to interstitium which may finally result in life threatening edema 
formation and may jeopardize survival of the tissue and causes organ dysfunction and 
may also contributes to pathogenesis of chronic cardiovascular diseases such as 
atherosclerosis and diabetes-associated vascular disease (Lum and Malik, 1996; van 
Hinsbergh 1997; Wojciak-Stothard et al., 1998, Libby et al., 2006; Pober and Sessa, 
2007; Stocker and Keaney, 2004; van Hinsbergh and Van Nieuw Amerongen, 2002; 
Mehta and Malik, 2006; Bazzoni, 2006; Yuan et al., 2007; Kumar et al., 2009). 
The maintenance of EC barrier integrity is crucial in maintaining physiological 
functions of different organs and is determined by the precise equilibrium between 
competing EC contractile forces generated by the actomyosin based EC contractile 
machinery and adhesive tethering forces generated by adhesive molecules located at 
endothelial cell-cell junctions and cell-matrix contacts (Garcia et al., 1995; Lum and 
Malik, 1996; Baldwin and Thurston 2001; Dudek and Garcia, 2001; Bogatcheva et al., 
2002; Shen et al., 2009). 
Inflammatory mediators such as thrombin, tumor necrosis factor alpha (TNF-α) and 
histamine disrupt the balance between contractile and adhesive forces, increase EC 
permeability via activation/stimulation  of multiple signaling mechanisms, leading to 
activation of EC contractile machinery, weakening of cell adhesion structures, opening 
of gaps between adjacent cells and hence finally leading to EC barrier dysfunction 
(Schnittler et al., 1990; Garcia et al., 1995; 1996; Rabiet et al., 1996; Wojciak-Stothard 
et al., 1998; Gündüz et al., 2003; Birukova et al., 2004). Thrombin also inhibits the Rho 
GTPase Rac1 activation (Aslam et al., 2012) finally leading to disruption of EC barrier 
integrity, which is followed by slow recovery of the EC barrier function.  
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The mechanisms of EC barrier restoration subsequent to barrier disruption in 
response to the permeability increasing factors are essential for the maintenance of 
basal endothelial monolayer permeability and to prevent edema formation. However 
the precise mechanisms involved in this recovery of EC barrier function still remains 
to be elucidated. Comparatively little is known about the maneuvers that control the 
restoration of compromised EC barrier function.  
Insulin is the principal hormone of metabolic homeostasis. Recent clinical 
findings demonstrate that intensive insulin therapy confers vasoprotective effects 
under inflammatory conditions and reduces diabetes associated major cardiovascular 
complications because of its anti-inflammatory and anti-atherosclerotic effects 
(Dandona et al., 2009; Kim et al., 2006; Nathan et al., 2005; Langouche et al., 2005).  
The aim of the present study was to elucidate the molecular mechanism by 
which insulin may restore the EC barrier function in response to thrombin-induced 
hyperpermeability. Special emphasis was laid on the potential role of Rho GTPase 
Rac1. The study was carried out in a well-established in vitro model of Human 
umbilical vein endothelial cells (HUVECs) and a model of isolated saline perfused rat 
hearts. 
 
1.2 Regulation of endothelial barrier function  
1.2.1   Endothelial cell-cell junctions  
Barrier function of vascular endothelium is mainly regulated by the dynamic 
opening and closure of gaps between intercellular junctions. These inter-endothelial 
junctions mediate cell-cell adhesion and facilitate communication between adjoining 
ECs and dynamically control the permeability of vessel wall endothelial barrier 
(Bazzoni and Dejana, 2004; Dejana, 2004 and 2008). 
In ECs, adherens junctions (AJs) are of fundamental importance in mediating 
endothelial cell-cell adhesion and have a prominent role for regulating normal 
functioning of the endothelial barrier (Bazzoni and Dejana, 2004; Wallez and Huber, 
2008; Dejana and Giampietro, 2012). AJs are predominantly composed of vascular 
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endothelial (VE)-cadherin linked to peripheral actin cytoskeleton present directly under 
the cell membrane. The interaction of AJs with the actin cytoskeleton is important for 
stabilization of junctions. VE-cadherin is present nearly in all vascular beds (Dejana et 
al., 1995; Lampugnani et al., 1995; Gao et al., 2000; Mehta and Malik, 2006; 
Vandenbroucke et al., 2008; Komarova and Malik, 2010; Giannotta et al., 2013). VE-
cadherin is required for the proper assembly of AJs and plays a crucial role in the 
maintenance of normal EC barrier function. VE-cadherin glues the adjacent ECs 
together by homotypic binding with VE-cadherin on the neighboring cell’s plasma 
membrane in calcium (Ca2+)-dependent manner. VE-cadherin has extracellular and 
cytoplasmic domains and is intracellularly linked to the actin cytoskeleton via family of 
catenin (Lampugnani et al., 1995; Iyer et al., 2004; Mehta and Malik, 2006; 
Vandenbroucke et al., 2008; Dejana et al., 2008; Prasain and Stevens, 2009; Shen et 
al., 2009; Komarova and Malik, 2010). Catenins not only serve as a structural linkage 
between VE-cadherin and actin cytoskeleton but also transduce biochemical signals 
for cell-cell communications. AJs disassemble in response to inflammatory mediators 
leading to an increase in EC permeability (Mehta and Malik, 2006). Thrombin-induced 
phosphorylation of p120 catenin may also contribute to AJ disassembly 
(Konstantoulaki et al., 2003). The stability of the VE-cadherin, catenins and actin 
cytoskeleton complex is essential to maintain the AJ integrity and restrictiveness of 
EC barrier (Vincent et al., 2004; Sallee, 2006; Alcaide et al., 2008; Zebda et al., 2013).  
 
1.2.2   Endothelial cell cytoskeleton 
ECs have a functional cytoskeleton which is composed of three primary 
elements: actin filaments, intermediate filaments and microtubules which are in 
constant communication with one another (Dudek and Garcia 2001; Chang and 
Goldman, 2004; Revenu et al., 2004; Prasain and Stevens, 2009; Shen et al., 2009). 
Endothelial cytoskeleton is very important for cell motility, EC shape, endo-or 
exocytosis and cell- cell adhesion. Among these filamentous structures actin filaments 
are best characterized for its role in regulating EC permeability.  
In ECs actin and myosin are major contractile components and together 
comprise of ~16% of total endothelial cellular proteins (Schnittler et al., 1990; Wong 
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and Gotlieb, 1990). Whereas actin alone represents about 5-15% of the total protein 
in ECs (Patterson and Lum, 2001) and exists in two different forms: in a monomeric 
globular form, known as G-actin and in a filamentous form, called F-actin (Tobacman 
and Korn, 1983). In general, the amount of F-actin and G-actin exists in an almost 
equal balance (Stossel et al., 1985).  
Permeability increasing factors such as thrombin increases polymerization of 
actin filaments that leads to actin reshaping to form stress fibers (Goeckeler and 
Wysolmerski, 1995; Ehringer et al., 1999; van Nieuw Amerongen et al., 2000a; 2000b; 
Sandoval et al., 2001; Mehta et al., 2002). Stress fibers are composed of bundles of 
actomyosin that are necessary for inducing cell contraction (Hotulainen and 
Lappalainen, 2006) and consists of relatively short F-actin filaments (Brenner and 
Korn, 1979 and 1980; Cramer et al., 1997; Heimann et al., 1999) whereas cortical 
actin rim is comprised of long F-actin filaments (De Matteis and Morrow, 2000; 
Heimann et al., 1999). Stress fibers extends throughout the cytosol, they generate 
centripetally (inward) directed tension, promotes gaps formation between adjacent 
ECs and may therefore contribute to endothelial hyperpermeability (Vouret-Craviari et 
al., 1998; Dudek and Garcia, 2001; Hotulainen and Lappalainen, 2006).  
  The actin cytoskeleton undergoes depolymerization and polymerization based 
upon cellular demand. Both hyper-polymerization of F-actin by Jasplakinolide and 
depolymerization of F-actin-induced by cytochalasin D interfere with EC barrier 
function (Waschke et al., 2005) suggesting that polymerization state of actin 
cytoskeleton is critical for the maintenance of EC barrier functions. Furthermore, 
inhibition of actin polymerization prevented force generation (Kolodney and 
Wysolmerski, 1992) as well as endothelial monolayer hyperpermeability in response 
to permeability increasing factors (Vouret-Craviari et al., 1998; Mehta et al., 2002;). 
Thus actin cytoskeleton is a key player and an important actuator for the regulation of 
EC barrier function. 
1.3 Endothelial contractile machinery 
Endothelial contractile machinery is another important regulator of EC barrier 
function. It is well documented that mechano-chemical interaction between actin and 
myosin is primarily believed to be involved in driving EC contractile machinery and 
Introduction 
5 
 
thereby EC barrier integrity (Schnittler et al., 1990). It is well established that activation 
of the EC contractile machinery leads to an increase in permeability. The activation of 
EC contractile machinery is mainly controlled by the phosphorylation state of the 
regulatory myosin light chain (MLC) (Wysolmerski and Lagunoff, 1991) and the 
balanced activities of MLC kinase (MLCK) (Lazar and Garcia., 1999), and MLC 
phosphatase (MLCP) (Härtel et al., 2007; Knapp et al., 1999; Verin et al., 2000)  
determine the net phosphorylation state of the MLC and actin-myosin contractility 
(Shen et al., 2009 and 2010).The major components of EC contractile machinery are 
MLC, MLCK and MLCP and are discussed below. 
MLC is a small protein of 20 kDa and phosphorylation of MLC induces a 
conformational change in the tertiary protein structure of myosin which increases actin-
myosin interaction, this actin-myosin interaction generates a contractile force that 
retracts adjacent ECs apart from each other, leading to intercellular gap formation and 
finally loss of barrier function, whereas MLC dephosphorylation causes stabilization of 
endothelial barrier (Wysolmerski and Lagunoff, 1990; Sheldon et al., 1993; Garcia et 
al., 1995; Goeckeler and Wysolmerski, 1995; Moy et al., 1996 and 2002; Gündüz et 
al., 2003; Takashima, 2009; Kasseckert et al., 2009).  
MLCK is a Ca2+/calmodulin (CaM)-dependent kinase which phosphorylates 
MLC at Ser-19 and/or Thr-18 (Goeckeler and Wysolmerski, 1995; Kamm and stull 
1986; Moy et al., 1993; Sheldon et al., 1993; Garcia et al., 1995; Amano et al., 1996; 
Hixenbaugh, 1997; Verin et al., 1998; Shen, 2010). It is well-established that MLCK 
becomes activated via Ca2+ dependent mechanisms in response to inflammatory 
mediators like thrombin and histamine which leads to an increase in MLC 
phosphorylation, finally leading to increase in endothelial monolayer permeability and 
leaky barrier (Sheldon et al., 1993; Dudek and Garcia, 2001).  
Initially in bovine pulmonary artery EC monolayers, the involvement of MLCK 
in the regulation of barrier permeability via MLC phosphorylation was discussed by 
Wysolmerski and Lagunoff (1990). Subsequent studies by using both in vivo and in 
vitro approaches/techniques have further elucidated the important role of MLCK in the 
regulation of permeability (Wainwright et al., 2003; Parker et al., 2000; Tinsely et al., 
2000; Yuan et al., 1997; Khimenko et al., 1996; Garcia et al., 1995; Sheldon et al., 
1993). 
Introduction 
6 
 
Besides MLCK, MLCP is also involved in controlling the phosphorylation state 
of MLC in ECs. Conversely, MLCP facilitates MLC dephosphorylation thus counteracts 
the MLCK activity, thereby terminating the tension, relaxes the actin cytoskeleton, and 
reduces the EC barrier permeability (Verin et al., 1995; Essler et al., 1998). The 
endothelial MLCP is a holoenzyme complex composed of three subunits, a regulatory 
myosin phosphatase targeting subunit (MYPT1, 130 kDa), a catalytic subunit, protein 
phosphatase 1 (PP1, 37-38 kDa) and a 20 kDa subunit of unknown function (Alessi et 
al., 1992; Shimizu et al., 1994; Shirazi et al., 1994; reviewed by Hartshorne et al., 
1998; Verin et al., 2000; Goeckeler and Wysolmerski, 2005). 
 It is well-established that MLCP activation is regulated through phosphorylation 
of MYPT1 at its two main inhibitory phosphorylation sites, Thr696 and Thr850 (Kimura 
et al., 1996) or through direct inactivation of the catalytic subunit, PP1 by CPI 17 (an 
endogenous inhibitor of PP1). Several kinases have been described to phosphorylate 
MYPT1 at one or both of these sites. The major well-known kinase is RhoA-dependent 
kinase (Rock) that phosphorylates MYPT1 at both sites and inhibits MLCP activity 
(Härtel et al., 2007; Pandey et al., 2006; Goeckeler and Wysolmerski, 2005; 
Hartshorne, 1998; Fukata et al., 2001) thereby promoting MLC phosphorylation, 
actomyosin contraction and finally leading to increased EC permeability (van Nieuw 
Amerongen et al., 1998; Essler et al., 1998; Birukova et al., 2004).  
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Figure 1.1 Regulation of EC barrier function by EC contractile machinery: Actin-
myosin contraction is increased by MLC phosphorylation (MLC~P) and is an important 
step in the regulation of the activation of the EC contractile apparatus. MLC is 
phosphorylated by (Ca2+/CaM)-dependent MLCK while dephosphorylated by MLCP. 
Activation of the EC contractile machinery leads to EC contraction and barrier 
dysfunction, whereas inactivation leads to relaxation and barrier stabilization. ML-7 is 
a specific inhibitor of MLCK while MLCP can be inactivated by RhoA/Rock. 
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1.4 Rho GTPases 
The members of the Rho-family of monomeric GTPases (RhoA, Rac1 and 
Cdc42) have been well recognized  to play an important role in regulating endothelial 
barrier integrity and have been implicated in controlling the endothelial actomyosin 
contractile machinery, actin cytoskeleton dynamics and integrity of cell adhesion 
structures (Wojciak-Stothard et al., 2001; Fukata and Kaibuchi, 2001; Wojciak-
Stothard and Ridley, 2002). Two Rho GTPases, Rac1 and RhoA, act antagonistically; 
have emerged as key regulators of  EC barrier function  (Essler et al., 1998 and 1999; 
Hall, 1998; Wojciak-Stothard et al., 2001; Ridley, 2001; Braga, 2002; Etienne and Hall, 
2002;  Mehta and Malik, 2006; Vandenbroucke et al., 2008; Dejana et al., 2008; Aslam 
et al., 2011).  
It is well-established that the Rho GTPase RhoA plays a vital role in regulating 
actomyosin contractile machinery in ECs and thereby is the key determinant of EC 
hyperpermeability (Carbajal and Schaeffer, 1999; Holinstat et al., 2003; Mehta et al., 
2001; Van Nieuw Amerongen et al., 1998 and 2000). RhoA, through its specific 
downstream effector kinase, Rock. inactivates MLCP via phosphorylation of MYPT1 
at its inhibitory sites which attenuates the phosphatase activity (Essler et al., 1998 and 
1999; Totsukawa et al., 2000; Verin et al., 2001; Birukova et al., 2004; Vandenbroucke 
et al., 2008; Kumar et al., 2009; Härtel et al., 2007) thereby resulting in net increase in 
phosphorylated regulatory MLC and actomyosin contractility which facilitates 
disruption of the endothelial barrier. RhoA is also known to induce derangement of 
actin cytoskeleton in terms of stress fibers formation and disassembly of endothelial 
AJs in response to thrombin, histamine or bradykinin leading to increased EC 
permeability (Birukova et al., 2004a; Birukova et al., 2004d; Wojciak-Stothard et al., 
2001; Wojciak-Stothard and Ridley, 2002; Essler et al., 1998 and 1999; Van Nieuw 
Amerongen, 2000). 
In contrast to RhoA, Rac1 is required for the stability of VE-cadherin mediated 
endothelial AJs and thus plays a role in the stabilization of the EC barrier function 
(Wojciak-Stothard et al., 2001; Waschke et al., 2004). Rac1 activation reorganizes the 
actin cytoskeleton at the cell periphery and thus strengthens the establishment of 
endothelial AJs (Hall, 1998; Wojciak-Stothard et al., 2001; Wojciak-Stothard and 
Ridley, 2002; Kumar et al., 2009) and also reduces the macromolecule permeability 
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of EC monolayers (Waschke et al., 2006). The activation of Rac1 is regulated by GDP-
GTP cycling, induced by specific guanine nucleotide exchange factors (GEFs), Tiam1 
and TrioN, which control the transition of the inactive GDP-bound conformation to the 
active GTP-bound conformation (Gao et al., 2004). The activation of Rac1 can be 
inhibited by the specific pharmacological inhibitor NSC23766, which specifically 
inhibits Rac1 activity by blocking the binding of the Rac1 specific GEFs Tiam1 and 
TrioN (Gao et al., 2004). Even though, much is still a mystery about the role of Rho 
GTPases in EC permeability, the activation of Rac1 appears to be a suitable approach 
to stabilize or recover EC barrier function in inflammatory situations. 
 
1.5 Endothelial barrier dysfunction: Endothelial hyperpermeability 
Endothelial barrier dysfunction is a significant problem and resulting vascular 
leakage is implicated in the pathogenesis of various diseases including inflammation, 
trauma, sepsis, diabetes associated vascular disease, atherosclerosis and acute lung 
injury. Various inflammatory conditions are associated with the deterioration of EC 
barrier function and pathophysiology is characterized by leakage of fluid, plasma 
proteins or small molecules in the extra vascular space leading to tissue edema which 
finally results into severe, sometimes life threatening organ dysfunction.  
There are three key mechanisms believed to be involved in inflammatory 
conditions that lead to endothelial hyperpermeability. (1) The cytoskeleton 
rearrangement: remodeling of cortical actin and generation of stress fibers, (2) 
activation of EC actomyosin based contractile machinery and (3) disassembly of AJs. 
All these elements together lead to formation of intercellular gaps, which perturb the 
normal EC barrier function (McDonald et al., 1999; Mehta and Malik, 2006).  
Thrombin, a procoagulant serine protease, is a central vascular mediator of 
inflammation and hemostasis, generated in the vessels from pro-thrombin circulating 
in blood. Thrombin induces rise in intracellular Ca2+ levels which phosphorylates MLC 
through activation of MLCK and RhoA/Rock signaling which downstream inhibits the 
MLCP finally leading to strong activation of EC contractile machinery and thereby 
contributes to thrombin-induced loss of EC barrier function (Lum and Malik, 1996; 
Dudek and Garcia, 2001; Coughlin, 2000; Bogatcheva et al., 2002). Thrombin-induced 
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increased vascular permeability has also been attributed to stress fiber formation. 
Thrombin also inhibits Rho-GTPase Rac1 activation (Aslam et al., 2012) that leads to 
disruption of endothelial AJs and thereby EC barrier integrity.  
Ischemia-reperfusion (I-R) also induces loss of EC barrier function and the 
resulting myocardial edema jeopardizes the functional recovery of vital organs such 
as heart during reperfusion and may inhibit survival of myocardial tissue (Garcia-
Dorado and Oliveras, 1993; Mehlhorn et al., 2001; Carden and Granger, 2000; Schäfer 
et al., 2003; Gündüz et al., 2006). I-R injury refers to edematous swelling of the 
reperfused tissue when the blood supply returns after an ischemic period (Dagenais 
et al., 1997; Eltzschig and Collard, 2004). This restoration of blood supply causes 
tissue inflammation due to neutrophil activation and release of cytokines. Previous 
reports indicate that reperfusion triggers the opening of intercellular gaps between ECs 
and Ca2+ dependent activation of the EC contractile machinery contributes to the 
barrier failure under reperfusion (Schäfer et al., 2003). Previously, in saline-perfused 
hearts, a rapid post ischemic edematous swelling of the myocardium has also been 
observed (Noll et al., 1999; Di Napoli et al., 2001). Better insights into the molecular 
mechanisms related to endothelial hyperpermeability is required for developing 
effective therapeutic strategies. 
 
1.6 Recovery of endothelial barrier function after barrier dysfunction 
The mechanism of recovery of EC barrier function is critical for the maintenance 
of basal permeability and is important to prevent the potentially fatal increase in EC 
permeability. Failure to recover EC barrier function likely underlies the morbidity and 
mortality associated with vascular diseases. In contrast to mechanisms involved in 
regulating barrier disruption, detailed knowledge of the signaling pathways responsible 
for recovery of EC barrier function is, at present, lacking. Permeability increasing 
mediators usually induce a reversible increase in EC permeability (Tiruppathi et al., 
1992; Moy et al., 1996; Mehta et al., 2002).  
The process of barrier recovery requires the reannealing of previously opened 
gaps between the adjacent cells, suppression or inactivation of EC contraction (Garcia 
et al., 1995, Gündüz et al., 2003) and strengthening of cell-cell adhesion structures 
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(Mehta et al., 2002; Quadri et al., 2003; Kouklis, 2004). AJs disassemble in response 
to thrombin, increasing EC permeability; however, AJs also possess the ability to 
reassemble. This reannealing of AJs causes reversal of increase in endothelial 
monolayer permeability and restoration of vascular endothelial barrier integrity (Lum 
and Malik, 1996; Dudek and Garcia, 2001; Lampugnani et al., 1995; Kouklis et al., 
2004; Broman et al., 2007; Dejana et al., 2008).  
Studies have shown the crucial role of Rho GTPases (Rac1 and CDC42) in 
regulating recovery of EC barrier function. Both Rac1 and CDC42-induce 
reorganization of actin cytoskeleton, apposition of AJs at the plasma membrane and 
thus promotes reannealing of AJs (Kaibuchi et al., 1999). Rac1 is reported to be 
involved in actin cytoskeleton remodeling and lamellipodia formation (Hall, 1998 and 
2005; Ehrlich et al., 2002). The mediators like oxidized lipids (Birukov et al., 2004), 
sphingosine 1- phosphate (S1P) (Singleton et al., 2005) ATP (Jacobson et al., 2006) 
and cAMP (Aslam et al., 2014) are known to restore EC barrier function by Rac1 
activation.  
 Several signaling pathways have been shown to contribute in regulating 
recovery of EC barrier function: (a) p120 catenin (Iyer et al., 2004), p120 catenin 
participates in regulating endothelial barrier restoration by controlling the stability of 
VE-cadherin expression and, hence, AJs stability. (b) Activation of focal adhesion 
kinase (FAK) (Holinstat et al., 2006) also plays an important role in regulating barrier 
restoration. FAK suppress RhoA activity via P190RhoGAP activation which in turn 
inhibits EC contraction and thereby induces recovery of EC barrier function (Quadri et 
al., 2003; Holinstat et al., 2006). (c) Angiopoietin 1 activation of Tie2 receptor (Mehta 
and Malik 2006), (d) FoxM1 transcription factor (Zhao et al. 2006), (e) Sphingosine 1- 
phosphate (S1P) (Hla, 2003). S1P, a biologically active lipid secreted by red blood 
cells and activated platelets has also emerged as potent barrier stabilizing factor in 
cultured ECs and in intact microvessels (Mcverry and Garcia, 2004; Peters and 
Alewijnse, 2007). S1P mediated its effects via a number of downstream targets 
including Rac1 mediated cytoskeletal reorganization that promoted AJs assembly and 
EC barrier enhancement (Mehta et al., 2005; Singleton et al., 2005). (f) cAMP signaling 
also contributes to the recovery of EC barrier function after thrombin-induced 
hyperpermeability (Aslam et al., 2014). Evidence indicates that an increase in the 
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concentration of cAMP can be EC barrier protective. The cAMP downstream activates 
two effector proteins, the protein kinase A (PKA) and Epac (de Rooij et al., 1998; 
Aslam et al., 2010). Both PKA and Epac downstream activates Rac1 (Birukova et al., 
2008 and 2010). Inhibition of these cAMP downstream effectors abrogates Rac1 
activation, re-establishment of AJs and impedes the recovery of EC barrier function 
(Aslam et al., 2014). Better knowledge of the signals responsible for reversing the 
endothelial hyperpermeability may therefore lead to novel anti-inflammatory 
therapeutic targets capable of preventing inflammatory diseases manifested by 
vascular leak. 
 
1.7 Insulin 
Insulin is a key regulator and essential hormone of metabolic homeostasis. 
Based on previous findings there is convincing evidence that in addition to its well-
known metabolic actions insulin also confers protective effects on the cardiovascular 
system and plays an important role in the normal functioning of the vasculature (Verma 
and McNeill, 1999; Mather et al., 2001).  
Insulin biological actions are mediated by specific cell surface receptors. Like 
many other cell types ECs also possess insulin receptors (IR) (~ 40,000 IR per cell) 
(Zeng and Quon, 1996) with intrinsic tyrosine kinase activity. The insulin receptor is a 
heterotetrameric transmembrane glycoprotein composed of two α and β subunits 
(Kahn, 1985; Kahn and Crettaz 1985; Rosen et al., 1987). Insulin initiates its action by 
binding to specific receptors on the surface of the cell. The specific binding of insulin 
to its cell surface receptor leads to autophosphorylation on the IR- β subunit and 
tyrosine phosphorylation of intracellular substrates that include insulin receptor 
substrate (IRS) family members and other signaling molecules such as Shc. IRS is an 
essential component of insulin signaling pathway. Phosphorylated IRS serve as 
docking proteins for several downstream effectors of insulin signaling such as 
phosphatidylinositol 3-kinase (PI3K) and Grb2 (White, 2002; Gual et al., 2005). 
Phosphorylation of IRS proteins on multiple tyrosine residues by the activated IR 
initiates the activation of PI3K (Montagnani et al., 2002). 
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 In response to insulin, two major signaling pathways are activated: the 
PI3K/Akt signaling pathway and mitogen activated protein kinase (MAPK) pathway 
(Myers and White, 2002; Taniguchi et al., 2006). Downstream from PI3K there is also 
an essential component of insulin signaling pathway called 3-phosphoinositide 
dependent protein kinase (PDK)-1. This kinase is crucial for the activation and 
phosphorylation of serine/threonine protein kinase Akt and atypical protein kinase C 
isoforms (Alessi et al., 1997; Vanhaesebroeck and Alessi, 2000). Protein kinase B 
(Akt) directly phosphorylates and activates endothelial NO synthase (eNOS) at Ser 
1177, resulting in enhanced eNOS activity which leads to increased production of Nitric 
oxide (NO) within a matter of minutes (Alessi et al., 1997; Dimmeler et al., 1999; 
Dimmeler and Zeiher, 1999; Vanhaesebroeck and Alessi, 2000; Montagnani et al., 
2001 and 2002; Kuboki et al., 2000; Zeng et al., 1996 and 2000). 
PI3K/Akt signaling pathway has been termed as “survival pathway”. It has been 
identified to confer protective effect against reperfusion injury of the heart (Hausenloy 
and yellon, 2004). PI3K/Akt is a major component in insulin signaling pathway and 
inhibition of PI3K blocks NO production in response to insulin, demonstrating its 
essential role in insulin stimulated production of NO (Zeng and Quon 1996; Zeng et 
al., 2000; Fisslthaler et al., 2003; Hartell et al., 2005). In vivo administration of insulin 
is also known to attenuate reperfusion-induced cell death through PI3K/Akt and eNOS 
signaling pathway (Gao et al., 2002).  
There is convincing evidence that insulin induces NO production in 
microvascular ECs and inhibition of eNOS not only prevented insulin-induced NO 
production but also in part antagonized insulin mediated  microvascular EC barrier 
stabilization (Gündüz et al., 2010). Insulin also prevents oxidant-induced EC barrier 
dysfunction by inducing the release of NO (Rath et al., 2006). Insulin also acts as a 
vasodilatory hormone that mainly depend on endothelium derived NO (Steinberg et 
al., 1994; Scherrer et al., 1993; Laine et al., 2000; Sundell et al., 2002; Scott et al., 
2002; Sundell and Knuuti, 2003; Vincent et al., 2006).  
It is well known that insulin inhibits thrombin-induced vascular smooth muscle 
cell (VSMC) contraction (begum et al., 2000). Insulin-induces the relaxation of VSMCs 
via activation of myosin-bound phosphatase and inhibition of Rho kinase activity via 
NO/cGMP-dependent pathway (begum et al., 2000, Sandu et al., 2001). In VSMCs 
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insulin negatively regulates Rho signaling by preventing RhoA activation via the 
NO/cGMP signaling pathway which leads to myosin-bound phosphatase activation, 
disorganization of actin cytoskeleton and vasodilation (begum et al., 2002). 
Previous reports indicate that insulin has profound protective effects in critical 
illness and in acute inflammatory conditions (Melin et al., 2002; Malmberg et al., 1995; 
Kinsley, 2004 Lewis et al., 2004; Furnary et al., 2004 Ritchie et al., 2004). Several 
reports have reported that insulin has direct protective effects on ECs (Aljada et al., 
2000 and 2001; Jeschke et al., 2004; Fischer-Rasokat and Doenst, 2003). 
Several clinical and experimental studies dealing with I-R could show that  
insulin dose at the time of reperfusion protects against the reperfusion-induced 
vascular injury in the heart (Melin et al., 2002; Malmberg et al., 1995; Ma et al., 2006). 
Insulin also protects cardiomyocytes against acute reoxygenation-induced hyper-
contracture via activation of survival pathway consisting of PI3K, eNOS and cGMP-
dependent protein kinase (PKG) (Abdallah et al., 2006).  
Insulin increases myocardial blood flow and reduces coronary vascular 
resistance in a dose dependent manner. Moreover the mortality rate was reduced in 
critically ill patients who were more than 3 days in intensive care unit provided with 
intensive insulin therapy (Van den Berghe et al., 2001; Furnary et al., 2003; Van den 
Berghe, 2004; Lewis et al., 2004; Krinsley, 2004; Jeschke et al., 2004). Several clinical 
reports also show that intensive insulin therapy has vasoprotective effects under 
inflammatory conditions (Van der Berghe, 2001; Melin et al., 2002; Ritchie et al., 2004; 
Langouche et al., 2005; Dandona et al., 2009) and reduces major cardiovascular 
complications in diabetics (Nathan et al., 2005). 
Previous reports indicate that in rat coronary microvascular endothelial 
monolayers, insulin not only stabilizes endothelial barrier under basal conditions but 
also antagonized the hyperpermeability-induced by inflammatory mediator, tumor 
necrosis factor alpha (TNFα) (Gündüz et al., 2010). This barrier stabilizing effect of 
insulin is mediated via PI3K/Akt and NO/cGMP-induced activation of Rac1 (Gündüz 
et al., 2010). However, the detailed mechanism of insulin mediated accelerated 
recovery of disrupted endothelial barrier integrity in response to permeability 
increasing factors is still elusive. 
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1.8 Aims and objectives of the study  
The main aim of the present study was to broaden our knowledge on the 
contribution of insulin-mediated recovery of EC barrier function under patho-
physiological conditions. Thrombin is used as a model inflammatory mediator, to 
activate EC barrier disrupting signaling or to induce EC monolayer hyperpermeability, 
followed by slow recovery of the EC barrier function. The mechanisms of EC barrier 
recovery are critical for the maintenance of basal monolayer permeability. Here the 
hypothesis was tested whether insulin can mediate the fast restoration/recovery of EC 
barrier function in response to thrombin-induced hyperpermeability. Moreover, a 
model of isolated saline perfused rat heart is applied to further prove the protective 
effects of insulin on endothelial barrier integrity in an intact coronary system. 
The following questions were addressed in this thesis. 
 Does PI3K/Akt pathway play a role in insulin-mediated restoration of EC 
barrier function? 
 Does insulin has any effect on inactivation of EC contractile machinery and 
fast re-establishment of AJs in response to thrombin-induced EC barrier 
failure? 
 Does RhoA/Rock signaling pathway play a role in insulin-mediated recovery 
of EC barrier function in response to thrombin challenge? 
 Does eNOS/NO pathway play a role in insulin-mediated EC barrier 
recovery? 
 Does Rho GTPase Rac1 play a role in insulin-mediated restoration of EC 
barrier function? 
 Does insulin protect the heart against reperfusion-induced injury and 
imminent life threatening edema, in the intact isolated saline perfused rat 
heart? 
 
To achieve these objectives a well-established in vitro model of HUVECs and a model 
of isolated saline-perfused rat hearts were used. Inflammatory mediator thrombin was 
present during the whole experimental period in order to imitate/emulate in vivo 
conditions. 
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The following experimental approaches were used to answer these questions. 
 Macromolecule albumin permeability across HUVEC monolayers was used 
as functional assay to assess the impact of insulin on EC barrier restoration. 
 Dynamics of activities of EC contractile machinery i.e. MLC and MYPT1 
phosphorylation was analyzed by Western blot analysis. 
 The effects of insulin on VE-cadherin based AJs were visualized by 
immunofluorescence confocal microscopy. 
 Activation of Rac1 was analyzed by pull down assay. 
 Myocardial water contents were determined by Langendorff perfusion 
system. 
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2. MATERIALS 
 
2.1 Laboratory instruments 
 
Beckman Allegra 64R centrifuge    Beckman Coulter, USA 
Beckman TL 100 ultracentrifuge    Beckman Coulter, USA 
Electroblot chambers     Biotech-Fischer, Reiskirchen,  
       Germany 
Electrophoresis apparatus     Biometra, Goettingen, Germany 
Gel documentation system  
(ChemiSmart 5000)  Peqlab, Erlangen, Germany 
Glas coverslips  Menzel, Braunschweig 
Glass ware       Schott, Mainz, Germany 
Hamilton syringe      Hamilton, Bonaduz, Switzerland 
Incubators       Heraeus, Hanau, Germany 
Laminar flow hood      Heraeus, Hanau, Germany 
LSM-510 Meta confocal microscope   Carl Zeiss, Jena 
Magnet stirrer      Jahnke und Kunkel, Staufen,  
       Germany 
Neubauer chamber      Superior, Marienfeld, Germany 
Phase contrast microscope    Olympus, Japan 
PH-Meter      WTW-Weinheim, Germany 
Photometer      Zeiss, Jena, Germany 
Power supply      Biometra, Goettingen, Germany 
Rocker       Biometra, Goettingen, Germany 
Shaker      Biometra, Goettingen, Germany 
Table top (centrifuge)     Eppendorf, Hamburg, Germany 
Tubes       Eppendorf-Netheler-Hinz, Germany 
Vortexer       Heidolph, Kelheim, Germany 
Water bath       Julabo, Seelbach, Germany 
Water demineralization unit    Millipore, Eschborn, Germany 
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2.2 Chemicals and consumables 
 
Acrylamide/Bisacrylamide (1:19)    SERVA, Heidelberg, Germany  
Solution 40%     
Ammonium persulfate     SERVA, Heidelberg, Germany 
Benzonase®       Merck, Darmstadt, Germany 
Bovine serum albumin     Sigma-Aldrich,Steinheim,Germany 
Bromophenol blue      Sigma-Aldrich, Steinheim,Germany 
Calcium chloride      Merck, Darmstadt, Germany 
Collagenase II      PAA Labs., Pasching, Austria 
Costar Transwell® filter membrane Greiner bio-one, Frickenhausen, 
Germany 
Complete® inhibitor cocktail    Roche, Mannheim, Germany 
Culture dishes      BD, Heidelberg, Germany 
Dimethyl sulfoxide      Sigma-Aldrich, Steinheim, Germany 
Dithiothreitol (DTT)     Amersham Pharmacia, UK 
EDTA       Carl Roth Karlsruhe, Germany 
EC basal medium® kit     PromoCell®, Heidelberg, Germany 
Eppendorf tubes (0.5, 1.5, 2 ml)    Eppendorf, Hamburg, Germany 
Falcon tubes (50 ml, 12 ml)    BD, Heidelberg, Germany 
FCS        PAA, Pasching, Austria 
Filter papers       Biotech-Fischer, Reiskirchen,  
       Germany 
Gentamycin       Gibco BRL, Eggenstein, Germany 
Glass cover slips      Menzel, Braunschweig, Germany 
Glycerol (100%)      Sigma-Aldrich, Steinheim, Germany 
Glycine       Carl Roth, Karlsruhe, Germany 
HBSS       PAA, Pasching, Austria 
HEPES       Sigma-ldrich,Steinheim,Germany 
Insulin (human recombinant)    Sigma-Aldrich, Steinheim 
Magnesium chloride     Fluka, Switzerland 
Magnesium sulfate      Merck, Darmstadt, Germany 
Manganese chloride     Merck, Darmstadt, Germany 
β-mercaptoethanol      Merck, Darmstadt, Germany 
Materials 
19 
 
Methanol       Merck, Darmstadt, Germany 
Millipore water      Millipore, Eschborn, Germany 
Nitrocellulose membrane     Schleicher und Schuell, Dassel,  
       Germany 
Non-fat milk powder     Applichem, Darmstadt, Germany 
Nonidet P-40      Sigma-Aldrich, Steinheim, Germany 
Penicillin/streptomycin     Gibco BRL, Eggenstein, Germany 
Paraformaldehyde      Merck, Darmstadt, Germany 
Pipette tips      Eppendorf, Hamburg, Germany 
Pipettes       Eppendorf, Hamburg, Germany 
PMSF       Sigma-Aldrich, Steinheim, Germany 
Ponceau S solution      SERVA, Heidelberg, Germany 
Potassium chloride      Merck, Darmstadt, Germany 
Potassium dihydrogen phosphate   Merck, Darmstadt, Germany 
Page ruler pre-stained protein ladder  Thermo Scientific, Braunschweig, 
Germany 
Rubber policeman      BD, Heidelberg, Germany 
Scalpal (disposble)      Feather, Osaka, Japan 
Sodium azide      Merck, Darmstadt, Germany 
Sodium bicarbonate     Carl Roth, Karlsruhe, Germany 
Sodium chloride      Carl Roth, Karlsruhe, Germany 
Sodium di-hydrogen phosphate    Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate     SERVA, Heidelberg, Germany 
Sodium fluoride      Sigma-Aldrich, Steinheim, Germany 
Sodium hydroxide      Carl Roth, Karlsruhe, Germany 
Sodium orthovanadate     Sigma-Aldrich, Steinheim, Germany 
Sterile filters (0.22 μm)     Sartorius, Goettingen, Germany 
Sterile pipettes      BD, Heidelberg, Germany 
Super signal-west® (ECL solution)   Fischer scientific, Niederlassung  
Nidderau, Germany 
Syringes (20 ml, 2 ml)     BD, Heidelberg, Germany 
TEMED       Sigma-Aldrich, Steinheim, Germany 
Thrombin       Sigma-Aldrich, Steinheim, Germany 
Tris base       Carl Roth, Karlsruhe, Germany 
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Triton X-100       SERVA, Heidelberg, Germany 
Trypan blue       Sigma-ldrich,Steinheim,Germany 
Trypsin-EDTA solution     Biochrom AG, Berlin 
Tween 20       Amersham Pharmacia, UK 
Whatman® 3 MM filter paper  Millipore, Eschborn, Germany 
 
2.3 Antibodies 
 
Primary antibodies: 
Antibodies       Source 
Anti-phospho Akt (Mouse IgG)   Cell Signaling Technology, USA 
Anti-phospho MLC (Rabbit IgG)   Cell Signaling Technology, USA 
Anti-phospho MYPT1     Merck Millipore, Schwalbach,  
       Germany  
(Thr850) (Rabbit IgG)       
Anti-Rac1-GTP (Rabbit polyclonal)  Cytoskeleton Inc., Denver USA 
Anti-VE-cadherin (Mouse IgG)    Beckman Coulter, Krefeld, Germany 
Anti-GAPDH      Cell Signaling Technology, USA 
 
Secondary antibodies: 
 
Antibody       Source 
Anti-Mouse IgG HRP-conjugated Amersham Biosciences, Heidelberg, 
Germany 
Anti-Rabbit IgG HRP-conjugated Amersham Biosciences, Heidelberg, 
Germany 
Anti-mouse IgG Alexa-Flour 488-conjugated Invitrogen, Karlsruhe, Germany 
 
2.4 Kits  
 
Rac1-Activation-Assay Kit      Cytoskeleton Inc., USA 
 
2.5 Inhibitors  
 
S961       Sigma, Steinheim, Germany 
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Wortmannin      Calbiochem, Darmstadt, Germany
  
L-NAME (Nω-Nitro-L-arginine methyl ester  Sigma, Steinheim, Germany 
Hydrochloride) 
ML-7 Hydrochloride     Enzo, Lörrach Germany  
Y27632       Calbiochem,Darmstadt, Germany 
NSC23766 (N-[N-(3, 5-difluorophenacetyl- 
L-alanyl)]-S-phenylglycine t-butyl ester (DAPT)) Calbiochem, Darmstadt, Germany 
 
2.6 Buffers 
 
2x-SDS sample buffer 
Tris-HCl (pH 6.8)     250 mM 
Glycerol      20 % 
SDS       4 % (wt/vol) 
DTT       1 mM (wt/vol) 
-mercaptoethanol     5% (vol/vol) 
Bromophenol Blue     0.001% (wt/vol) 
NaF       20 mM 
Na-orthovanadate     1.5 mM 
 
10x TBS (pH 7.4) 
Tris-HCl       100 mM 
NaCl        1.6 M 
TBS Tween (TBST) 
1x TBS       1000 ml 
Tween 20       1 ml (0.1%, vol/vol) 
 
10X PBS (pH 7.4) 
NaCl        1.37 M 
KCl        27 mM 
Na2HPO4       0.1 M 
KH2PO4       17 mM 
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Rac1 pull down assay  
Lysis buffer 
HEPES      25 mM 
NaCl        150 mM 
EDTA       1 mM 
MgCl2       5 mM 
Na-orthovanadate      2 mM 
DTT        5 mM 
NaF        10 mM 
Triton-X-100       0.5% 
PMSF       0.5 mM 
Glycerol       2% 
Supplemented with complete® protease inhibitor cocktail 
 
Wash buffer 
Tris-HCl (pH 7.4)      25 mM 
NaCl        150 mM 
MgCl2        10 mm 
Triton X-100       1% 
PMSF       0.5 mM 
Supplemented with complete® protease inhibitor cocktail 
 
2.7 Softwares 
 
Microsoft Word 2007 Microsoft Corp., USA 
Microsoft Excel 2007 Microsoft Corp., USA 
Microsoft Power Point 2007 Microsoft Corp., USA 
Microsoft Windows XP Professional  Microsoft Corp., USA 
Quantity one analysis software Bio Rad, Hercules, USA 
LSM 510 Carl-Zeiss, Jena, Germany  
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3. METHODS 
 
3.1 Cell culture 
Preparation of human umbilical vein endothelial cells (HUVECs) 
Media, sera, buffers and growth supplements 
 
Collagenase solution: 
HBSS (Hank´s balanced salt solution)    x ml 
Collagenase II, 293 IU/mg (wt/vol)     0.025% 
CaCl2         1.5 mM 
MgCl2          0.5 mM 
 
Endothelial cell culture medium  
EC basal medium (PromoCell®) supplemented with 
Fetal calf serum (FCS; vol/vol)      10% 
EC growth supplement/Heparin (wt/vol)     0.4% 
Hydrocortisone (wt/vol)       0.1% 
Basic fibroblast factor (wt/vol)     1 ng/ml  
Epidermal growth factor (wt/vol)     0.1 ng/ml  
Penicillin/streptomycin (vol/vol)      2% 
Trypsin/EDTA       0.05% 
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Procedure: Human umbilical cords were obtained from University Hospital Giessen 
after approval from hospital ethics committee. HUVECs were prepared from freshly 
collected umbilical cords according to Jaffe et al., 1973, with some changes. After 
cleaning, the umbilical vein was cannulated and rinsed with HBSS to clear away the 
traces of blood. To detach the HUVECs from the vessel wall the lumen of the vein was 
filled with collagenase solution and incubated for 30 min at 37°C.  After incubation the 
collagenase solution containing the primary HUVECs, was gently flushed from the vein 
by perfusion with 30 ml of HBSS containing 3% (vol/vol) FCS, to inactivate the 
collagenase activity. The effluent was collected in a 50 ml tube and centrifuged at 250 
× g for 5 min at room temperature. The supernatant was discarded and the cell pellet 
was resuspended in EC culture medium containing 0.1% (vol/vol) gentamycin. 
Thereafter, the cell suspension in EC culture medium was seeded in 1-3, 10 cm cell 
culture dishes and incubated at 37°C with 5% CO2 for 3 hrs. Afterwards, cells were 
washed with HBSS to clear away the cell debris, non-adherent and non-ECs and were 
incubated with EC culture medium supplemented with 0.1% (vol/vol) gentamycin with 
5% CO2 at 37°C. After 24 hours the EC culture medium was replaced with fresh EC 
culture medium and HUVECs were grown to confluence. 
 
3.2 Sub- culturing of HUVECs 
After reaching confluency, primary HUVECs were trypsinized in phosphate-
buffered saline (PBS) [composition: 137 mM NaCl, 2.7 mM KCl, 1.7 mM KH2PO4, and 
10 mM Na2HPO4; pH 7.4, supplemented with 0.05% (wt/vol) trypsin, and 0.02% 
(wt/vol) EDTA] for approximately 1-5 min. at 37°C to allow the majority of the cells to 
detach from the cell culture dish and the digestion was stopped by adding FCS. 
Trypsinated cells were centrifuged at 250 × g for 10 min and resuspended into EC 
culture medium and seeded at a density of 2×105 cells/cm2 on Transwell® filters (for 
permeability) or on 35 mm or 60 mm dishes (for Western blot analysis and pull down 
assay). For immunostaining and Confocal microscopy HUVECs were seeded on 25 
mm glass coverslips. The experiments were performed with confluent HUVEC 
monolayers of passage 1-2. 
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3.3 General experimental protocol 
 The basal medium used to perform experiments was HBSS supplemented 
freshly with 1.2 mM MgCl2 and 1.3 mM CaCl2. After an initial equilibration period of 30 
min on heating plates at 37°C prior to addition of drugs, agents were added as 
indicated. Stock solutions of insulin, thrombin, S961, ML-7, Y27632, L-NAME and 
wortmannin were prepared immediately before use. Stock solution of insulin was in 25 
mM HEPES and stock solutions of L-NAME, thrombin, S961 and Y27632 were 
prepared with basal medium. Stock solutions of wortmannin and ML-7 were prepared 
with dimethyl sulfoxide (DMSO). HUVECs were incubated with appropriate volumes 
of these solutions yielding final solvent concentrations < 0.1% (vol/vol). The same final 
concentrations of basal medium, DMSO or HEPES were also added in all respective 
control experiments. In those experiments where pharmacological inhibitors were 
used, the cells were preincubated with inhibitors for 30 min before addition of insulin 
as mentioned in figure legends. In a set of pilot experiments, the optimal effective 
concentration of the drugs used in this study were determined. The agents were used 
in their optimal effective concentrations as follows: insulin 1 IU/ml, thrombin (0.2 - 0.3 
IU/ml), S961 (1 M), wortmannin (0.01 M), ML-7 (10 M), Y27632 (1 M), L-NAME 
(100 M) and NSC23766 (50 M.) 
 
3.4  Protein analysis 
 
3.4.1 Preparation of protein samples 
 HUVECs were lysed in 150 l 2x SDS sample buffer [Buffer composition: 250 
mM Tris/HCl; pH 6.8, 4% (wt/vol) SDS, 20% (vol/vol) glycerol, 20 mM NaF, Na-
orthovanadate 1.5 mM, 0.001% (wt/vol) bromophenol blue, and 10 mM DTT (added 
freshly before use)]. Afterwards, 50 IU/ml Benzonase® and 2 mM MgCl2 was added 
freshly before use and lysate was collected in a 1.5 ml Eppendorf tube by scraping 
with the help of a rubber policeman. Samples were denatured at 95°C for 3 min and 
used immediately for electrophoresis or stored at -20°C for future use. 
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3.4.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Resolving gel buffer:   Tris/HCl; pH 8.8  120 mM 
Stacking gel buffer:   Tris/HCl; pH 6.8 120 mM 
 
10x Gel running buffer 
Tris   250 mM 
Glycine   2.0 M 
SDS (wt/vol)   10% 
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SDS gels 
The composition of gels of different percentages is given below: 
Gels  Resolving Gels 
(For 2 gels) 
 
Stacking 
Gels 
Solutions 5 % 10% 12.5% 6% 
Acrylamide/Bisacrylamide 
(1:19)  40% (wt./vol) 
2.25 ml 4.50 ml 5.63 ml 0.75 ml 
 
Resolving gel buffer 6.75 ml 6.75 ml 6.75 ml ----- 
Stacking gel buffer ----- ----- ----- 0.75 ml 
Millipore water 8.70 ml 6.45 5.33 ml 4.43 ml 
SDS 10%  (wt./vol) 180 µl 180 µl 180 µl 60 µl 
APS 10%  (wt./vol) 150 µl 150 µl 150 µl 37.5 µl 
TEMED 15 µl 15 µl 15 µl 7.5 µl 
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Procedure:  Glass plates, spacers and combs were cleaned with water and ethanol, 
then gel apparatus was assembled and the resolving gel solution was poured and 
layered with ethanol or water. The gel was left to polymerize for 1 hour at room 
temperature. Once the gel was polymerized the top of the gel was completely rinsed 
with water. The layer of water was removed. The stacking gel solution was prepared 
immediately before use and was poured on top of the resolving gel cautiously so that 
there was no bubble. The comb was inserted and the stacking gel was left to 
polymerize at room temperature for 30 min. After removing the comb carefully (not to 
damage the wells) 1x running gel buffer was added to the chamber and the sample 
wells were cleaned to remove the unpolymerized acrylamide with the same buffer 
using a syringe. Protein samples were loaded into the wells and the gel was run at 
120 volts for 3 hrs. The run was stopped when bromophenol blue had passed through 
the gel. The molecular weight of proteins was determined by comparison with 
PageRuler TM  prestained protein ladder. 
 
3.5 Western blot analysis 
 Proteins separated by SDS-PAGE were transferred onto a nitrocellulose 
membrane by semi-dry blotting method. Later on specific proteins were 
immunodetected by using specific antibodies. 
 
Materials and solutions 
 Blotting chamber 
 Nitrocellulose membrane,  
 Whatman® 3 MM filter paper, 
 Blotting buffer 150 mM Glycine; 25 mM Tris/HCl, pH 8.3 and 10% (vol/vol) 
methanol 
  Millipore water 
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Procedure: Nitrocellulose transfer membrane and six pieces of Whatman® 3 MM 
filter papers, cut to the same size and dimensions as the gel. The graphite blotting 
chamber was set up as follows: Three sheets of filter paper (Whatman® 3 MM) 
soaked in blotting buffer, were placed in the center of the graphite anode of the 
blotting chamber. Nitrocellulose membrane equilibrated in blotting buffer for 10-15 
min placed on top of these sheets of filter paper. After briefly equilibrating with 
blotting buffer, the SDS-gel (only resolving gel) was layered on top of the 
nitrocellulose membrane, carefully avoiding air bubbles. Three sheets of filter 
paper, presoaked in blotting buffer, were placed on top of the gel followed by the 
graphite cathode of the blotting chamber. Transfer was achieved by application of 
0.8 mA/cm2 current for approximately 1 hour. 
 
3.5.1 Ponceau staining of transferred proteins 
After blotting, the membrane was stained with Ponceau-S solution to observe 
the efficiency of protein transfer. This stain is reversible and gives pink bands on a 
light background. The nitrocellulose membrane was washed with Millipore water for 1 
min, incubated in Ponceau-S solution for 2-3 min with constant shaking at room 
temperature. Afterwards the membrane was destained by washing in Millipore water 
to the desired contrast and photographed. To destain completely, the membrane was 
washed with 1x Tris-buffered saline (TBS) plus 0.1% Tween 20 under constant 
shaking at room temperature. 
 
3.5.2 Immunodetection of proteins 
Solutions: 
10x (TBS) 
Tris/HCl (pH 7.4)       100 mM 
NaCl      1.6 M 
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TBS Tween (TBST) 
1x TBS 
0.1% (vol/vol) Tween 20 
 
Blocking-buffer and antibody-dilution buffer 
After a brief washing with Millipore water and 1x TBST and before the 
immunological detection of relevant proteins, the binding sites of unspecific proteins 
were blocked by 5% (wt/vol) non-fat dried milk powder in 1x TBST (Milk) or 5% (wt/vol) 
BSA in 1x TBST for 1 hour at room temperature with constant rocking 
 
Primary Antibodies 
Antibody       Dilution   Dilution buffer 
Anti-phospho Akt (Mouse IgG)       1:1000   3% BSA 
Anti-phospho MLC (Rabbit IgG)      1:1000   3% BSA 
Anti-phospho MYPT1 (Thr850) (Rabbit IgG)  1:1000   3% BSA 
Anti-Rac1 (Rabbit IgG)     1:1000   3% BSA 
Anti-GAPDH      1:2000   3% BSA 
Secondary antibodies, horseradish peroxidase (HRP)-labeled 
Antibody     Dilution   Dilution buffer 
Anti-rabbit IgG     1:1000    5% milk powder 
Anti-mouse IgG     1:1000    5% milk powder 
Anti-mouse IgM     1:2000   5% milk powder 
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Procedure: After blocking, the membrane was incubated overnight with primary 
antibody at 4°C with gentle shaking. The membrane was then washed at room 
temperature with 1x TBST 3-4 times for 5-10 min each with constant rocking and 
incubated with HRP- conjugated secondary antibody for 1 hour at room temperature.  
 
3.5.3 Enhanced chemiluminescence (ECL) 
After incubation with the secondary antibody, membrane was then washed 2-3 
times as stated before and then incubated with enhanced chemiluminescence (ECL) 
solution (30 seconds to 1 minute). The appearing luminescence was detected and 
recorded with Peqlab, ChemiSmart gel documentation system as per manufacturer´s 
instructions and images were analyzed by using Quantity One software (Bio-Rad). 
 
3.6 Measurement of endothelial monolayer permeability 
 The permeability of trypan blue-labelled albumin across HUVEC monolayer 
was measured as described by Noll et al., 1999, using a two compartment system. 
The system consists of “luminal” (upper) and “abluminal” (lower) compartments. The 
compartments were separated by a filter membrane (with pore size 0.4 μm, 6.5 mm 
diameter).  The cells were cultured in luminal compartment on the membrane of the 
Transwell® filters till confluence. HBSS supplemented with 1.2 mM MgCl2 1.3 mM 
CaCl2 and 2% (vol/vol) FCS used as a basal medium was added in both 
compartments. The luminal compartment containing the HUVEC monolayer had 2.5 
ml volume of this medium while the abluminal compartment contained 6.6 ml of the 
medium. The fluid in the "abluminal" compartment was constantly stirred using 
magnetic stirrers. This system measures transendothelial flux from luminal to 
abluminal compartments in the absence of hydrostatic pressure gradients. In the 
luminal compartment final concentration of 60 µM of the trypan blue-labelled albumin 
was added. The appearance of trypan blue-labelled albumin from the luminal to the 
abluminal compartment was monitored continuously after every 60 seconds by 
pumping the liquid through a spectrophotometer (Specord 10, Zeiss Jena, Germany). 
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To avoid measurement artifacts a two-wavelength measurement mode was used 
(control 700 nm versus trypan blue 600 nm). 
The albumin flux (F, measured in mol/ (sec x cm2) across HUVEC monolayer 
surface area (S) was calculated as the increase in albumin concentration (d[A]2) during 
the time interval (dt) in the lower compartment with the volume (V) as follows: 
 
 
 
The combined permeability coefficient (P [cm/sec]) of both EC monolayer and filter 
membrane was calculated as: 
 
 
Where [A]1 and [A]2 are the albumin concentrations in the luminal and abluminal 
compartments, respectively. 
 
 
Figure 3.1.    Two compartment system of measuring trypan blue- labelled albumin 
permeability across the HUVEC monolayer 
Luminal  
Abluminal 
d [A]2 /  dt x V 
F =  ------------------------ (1) 
S 
F 
P = ------------------------ (2) 
([A]1 – [A]2) 
Twocompartmentsystem 
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3.7 Immunofluorescence microscopy  
Solutions and materials: 
Blocking buffer consists of 5% (vol/vol) FCS and 5% (wt/vol) BSA in 1x PBS 
Primary Antibodies 
Antibody      Dilution   Dilution buffer 
Anti-VE-cadherin (Mouse IgG)   1:100   blocking buffer 
 
Secondary Antibodies 
Antibody      Dilution   Dilution buffer 
Anti-mouse IgG     1:400   PBS 
(Alexa fluor 488) 
 
Protocol: HUVECs were grown on glass cover slips in 35 mm2 culture dishes until 
confluence. After treatments, cells were washed thrice with 1x PBS (pH 7.4) and then 
fixed with 4% paraformaldehyde for 20 min at room temperature or ice cold 100% 
methanol for 20 min at -20°C. Afterwards cells were washed three times for 10 min 
each with 1x PBS and permeabilized with 1x PBS containing 0.2% (vol/vol) Triton X-
100 at 37°C for 20 min. The cells were then washed 2-3 times with 1x PBS. Non-
specific binding was blocked by incubating cells with blocking solution (5% (wt/vol) 
BSA and 5% (vol/vol) FCS in 1x PBS) for 45 min. Cells were incubated with respective 
primary antibody in a dilution of 1:100 in blocking solution overnight at 4°C, washed 
three times with 1x PBS for 10 min each and subsequently incubated with secondary 
antibody tagged with Alexa fluor 488 in a dilution of 1: 400 for 1 hour at room 
temperature followed by 2-3 times gently washed with 1x PBS.  
The coverslips were finally mounted onto glass objective slides with a drop of 
commercial mounting solution. Confocal images were obtained and analyzed by using 
laser scanning microscopy (Carl Zeiss LSM 510, Jena, Germany). Fluorophores were 
excited by using argon (492 nm) and He-Ne (545 nm) lasers. Image acquisition and 
analysis was performed using software provided with the confocal microscope.  
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3.8 Detection of activated Rac1 
Rac1 belongs to Rho family of small GTPases. The activation state of Rac1 
was assessed by pull down assay. The assay is based on the principle that only the 
interaction of active form of the GTPase with its specific downstream effectors. The 
assay was performed according to the manufacturer’s instructions using the Rac1 p21 
binding domain (PBD) of p21-activated protein kinase 1 (PAK1), which leads to its 
activation, therefore, the p21 binding domain (PBD) of PAK 1 can be used as a probe 
to specifically isolate activated GTP-bound Rac1. 
 
Procedure: Confluent HUVEC monolayers were stimulated with insulin and thrombin 
as described in respective figures. Subsequently the cells were washed with ice-cold 
PBS and lysed with 600 l of lysis buffer (composition of the buffer: 25 mM Hepes; pH 
7.4, 150 mM NaCl, 1 mM EDTA, 5 mM MgCl2, 2 mM Na-orthovanadate, 10 mM NaF, 
5 mM DTT, 0.5 mM PMSF, 0.5% (vol/vol) Triton X-100, 2% (vol/vol) glycerol and 
supplemented with Complete® protease inhibitor cocktail) on ice for 10 min. The cells 
were harvested by cell scraper, lysate were transferred to pre-labelled sample tubes 
on ice. The lysate was centrifuged for 1 minute at 14000 x g at 4°C. 600 g of cell 
lysates were incubated with 10 g of GST-PAK beads (Cytoskeleton Inc.) at 4°C for 
40 min.  The beads were washed four times with wash buffer (composition of the wash 
buffer: 25 mM Tris-HCl; pH 7.4, 10 mM MgCl2, 1% (vol/vol) Triton X-100, 0.5 mM 
PMSF, 150 mM NaCl, and Complete® protease inhibitor cocktail), The pellet containing 
the beads with active Rac1 was eluted in 40-50 l of Laemmli sample buffer, boiled at 
95°C for 5 min and loaded on 12.5% SDS gel. Bound Rac1 protein was then detected 
by Western blot using specific polyclonal antibodies against Rac1 (Cytoskeleton Inc; 
Denver). For the cross comparison of Rac1 activation (level of GTP-bound Rac1) the 
total amount of Rac1 in cell lysates was used as a control. 
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3.9 Determination of myocardial water content 
All experiments were performed in accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the German law of animal 
welfare. Hearts from male Wistar rats with an average weight of 250-g were excised 
rapidly, and were mounted immediately after isolation on a Langendorff perfusion 
system in a temperature-controlled chamber (37°C), as previously described by (Noll 
et al., 1999)  with some modifications. Hearts were then perfused with Krebs-Henseleit 
buffer (composition of the buffer in mM: (NaCl 140, NaHCO3 24.0, MgSO4 1.0, KH2PO4 
0.4, KCl 2.7, CaCl2 1.8 and glucose 5.0) for 30 min (10 ml/min) prior to each 
experiment. The buffer pH was maintained 7.4 by gassing with carbogen (95% O2 and 
5% CO2) and filtrated with 0.45 M diameter membrane filters. Hearts were then 
exposed to one of the following protocols: (a) Normoxic (Nor) conditions for 90 min (b) 
hypoxia for 60 min  followed by 30 min of reperfusion (Rep) (c) hypoxia for 60 min 
followed by 30 min of reperfusion with insulin 0.1 IU/ml, during first 10 minutes of 
reperfusion, (d) 60 min of hypoxia followed by 30 min of reperfusion in which 
NSC23766, a specific Rac1 inhibitor, was added to the perfusion medium during last 
20 min of hypoxia and first 10 min of reperfusion in the presence of insulin (during first 
10 min of reperfusion only).The normoxic perfusion (10 ml/min) was with Krebs-
Henseleit buffer gassed with 95% O2 (vol/vol)/5% CO2 (vol/vol), the thermostatic heart 
chamber was flushed with humidified air, and hypoxic perfusion with Krebs-Henseleit 
buffer with humidified 95% N2 (vol/vol)/5% CO2 (vol/vol). At the end of each 
experiment, wet weight and after 24 hrs. dry weight of the perfused rat hearts were 
measured. Myocardial water content was calculated as follows:  
Myocardial water content = wet weight- dry weight 
 
Myocardial water content per 100 g heart weight =  
  
Wet weight - dry weight 
× 100 
Dry weight 
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3.10 Statistical analysis 
Data are expressed as means ± SEM of 3-5 experiments from independent cell 
preparations. The comparison of means between groups was performed by one way 
analysis of variance (ANOVA) followed by a Student-Newman-Keuls post-hoc test. 
Changes in parameters within the same group were assessed by multiple ANOVA 
analysis. Probability (P) values of less than 0.05 (P< 0.05) were assumed significant. 
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4. RESULTS 
 
4.1 Insulin enhances the recovery of EC barrier function in response to 
thrombin challenge 
In the first step the effect of insulin on recovery of EC barrier function disrupted 
by inflammatory agent thrombin was analyzed. As shown in Figure 4.1 exposure of 
ECs to thrombin (0.2 IU/ml) caused a robust increase in EC permeability which peaked 
within ~10-15 min in response to thrombin challenge and slowly returned to basal level 
approx. within 2 hrs. In the presence of insulin the thrombin-induced hyperpermeability 
was significantly reduced which was observed at all concentrations of insulin. 
Furthermore insulin-induced a fast restoration of EC barrier function in response to 
thrombin challenge, as was reflected by more rapid decrease in permeability to 
albumin towards basal level, and remained at lower level for the whole period of 
observation. The time required for the 50% recovery of EC monolayer permeability 
from the maximum increase of permeability was significantly less in the presence of 
insulin (~25 min vs. ~ 51 min, for insulin (1 IU/ml) plus thrombin and thrombin alone, 
respectively). Thus insulin accelerated restoration of EC barrier function, as was 
characterized by more rapid recovery of endothelial permeability to the basal level. 
This restoration of EC barrier function by insulin was concentration-dependent and 
was significant already at 0.01 IU/ml concentration of insulin (equivalent to ~ 50nM). 
Furthermore, the maximum reduction in macromolecule permeability was at 1 IU/ml of 
insulin concentration as shown in Figure 4.1. Therefore, this concentration of insulin 
was used for all subsequent experiments. 
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Figure 4.1 Effect of insulin on thrombin-induced hyperpermeability.  
HUVEC monolayers were exposed to thrombin (0.2 IU/ml) in the presence or 
absence of different concentrations of insulin (0.01, 0.1, and 1 IU/ml) or vehicle 
(control) as indicated. Data are mean ± SEM of 5 separate experiments of independent 
cell preparations; *P<0.05 versus control; #P<0.05 versus thrombin alone. 
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4.2 Effect of insulin on VE-cadherin mediated endothelial adherens junctions 
in response to thrombin challenge 
One of the major regulators of EC barrier integrity is the actin cytoskeleton 
anchored AJs consisting of VE-cadherin, which together with associated family of 
catenins seals the adjoining cells together and thereby limits the passage of 
macromolecules across the vessel wall (Dejana et al., 2008; Lampugnani et al., 1995). 
Therefore, the effect of insulin on VE-cadherin dynamics at cell-cell junctions after 
thrombin challenge was analyzed. 
VE-cadherin was decorated at the cell-cell junctions under basal conditions 
(Figure 4.2, 0 min). However, exposure of HUVEC monolayers to thrombin (0.3 IU/ml) 
resulted in drastic disappearance of VE-cadherin from cell borders within 10 min, 
leading to intercellular gap formation and an increase in permeability. Thrombin effect 
was very rapid and is followed by slow reappearance of VE-cadherin at cell-cell 
junctions. This thrombin effect was attenuated in the presence of insulin (1 IU/ml). 
Furthermore in thrombin challenged cells, insulin promoted fast re-appearance of VE-
cadherin at cell-cell junctions within 10 min and was even more pronounced at 30 min, 
showing protective effect of insulin against thrombin-induced loss of AJs, indicating 
that insulin strengthens as well as promotes quick re-establishment of cell-cell 
adhesion structures, thus accelerates recovery of EC barrier function after thrombin-
induced EC barrier breakdown.  
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Figure 4.2   Effect of insulin on thrombin-induced VE-cadherin localization and 
EC monolayer disruption. HUVECs were grown to confluence on glass cover slips 
and were exposed to thrombin (0.3 IU/ml) in the absence or presence of insulin (1 
IU/ml for 10 min) for indicated time periods. Methanol fixed and immunostained for VE-
cadherin. Scale bar 20 µm; shown are representative figures of VE-cadherin 
immunostaining of five separate experiments with independent cell preparations. 
 
4.3   Role of insulin receptors in insulin-mediated endothelial barrier recovery 
Like many other cell types ECs also express insulin receptors (Zeng et al., 
2000; Nitert et al., 2005). Therefore in the next step the involvement of insulin 
receptors in the EC barrier restoration effects of insulin was analyzed. In these 
experiments S961, a highly specific insulin receptor antagonist (Schaffer et al., 2008) 
was applied to block insulin receptors. Preincubation of ECs for 30 min with S961 (1 
µM) abolished the barrier recovery effect of insulin in response to thrombin-induced 
hyperpermeability as shown in Figure 4.3, indicating a receptor-mediated effect. 
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Figure 4.3 Role of insulin receptors on insulin-mediated endothelial barrier 
recovery. HUVEC monolayers were exposed to thrombin (0.2 IU/ml) in the presence 
or absence of insulin (1 IU/ml) or vehicle (control) as indicated. In a set of experiments 
ECs were exposed to thrombin in the presence of S961 (1 µM) plus insulin. Data are 
mean ± SEM of five separate experiments of independent cell preparations; *P<0.05 
versus control; #P<0.05 versus thrombin alone; n.s.: not significantly different from 
thrombin alone. 
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4.4  Role of PI3K/Akt pathway in insulin-mediated barrier recovery in HUVECs. 
There is convincing evidence that in ECs insulin mediates most of its effects via 
activation of PI3K/Akt pathway (Zeng et al., 2000; Hermann et al., 2000). Protein 
kinase B (Akt) is a downstream effector of PI3K, therefore, the effect of insulin on Akt 
activation (phosphorylation) was analyzed by Western blot analysis using a 
phospho-specific antibody against Akt. Insulin-induced a rapid increase in Akt 
phosphorylation in HUVECs as shown in Figure 4.4A. Phosphorylation of Akt reached 
its maximal within 5 min and sustained over the maximum indicated periods of 
observation as shown in Figure 4.4A 
In order to determine the contribution of PI3K in insulin-mediated EC barrier 
recovery in response to thrombin-induced hyperpermeability, the effect of specific 
PI3K inhibitor wortmannin was investigated. ECs were pre-incubated with specific 
PI3K inhibitor wortmannin (Wort: 0.1 µM) for 30 min. As shown in Figure 4.4B inhibition 
of PI3K with wortmannin completely abolished the insulin-mediated restoration of EC 
barrier function. 
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Figure 4.4   Role of PI3K/Akt pathway in insulin-mediated EC barrier restoration 
Effect of Insulin on Akt phosphorylation (pAkt). (A) Representative Western blots of 
Akt phosphorylation. HUVECs were incubated with insulin (1 IU/ml) for different time 
intervals (min) as indicated. Western blotting was performed with an anti phospho-Akt 
antibody. The same membranes were reprobed with anti-GAPDH antibody as loading 
control. The Western blots are representative of 3 different experiments using 
independent cell preparations. 
(B) HUVEC monolayers were challenged with thrombin (0.2 IU/ml) in the absence or 
presence of insulin (1 IU/ml) or preincubated with PI3K inhibitor wortmannin (Wort; 0.1 
M) for 30 min plus insulin plus thrombin or vehicle (control) as indicated. Data are 
mean ± SEM of five separate experiments of independent cell preparations. *P<0.05 
versus control; #P<0.05 versus thrombin alone; n.s.: not significantly different from 
thrombin alone. 
 
 
4.5  The effect of eNOS inhibition on insulin-mediated EC barrier restoration  
 Insulin activates EC nitric oxide synthase (eNOS) and hence induces NO 
production (Zeng et al., 2000; Montagnani et al., 2001 and 2002) and thereby may 
stabilize microvascular EC barrier function (Gündüz et al., 2010). Therefore, the 
involvement of eNOS in insulin-mediated recovery of EC barrier function in response 
to thrombin-induced hyperpermeability was analyzed by using a specific well-
established eNOS inhibitor L-NAME. In these experiments endothelial monolayers 
were preincubated with L-NAME (100 M) for 30 minutes. As shown in Fig. 4.5, 
inhibition of eNOS had no significant effect on insulin-mediated EC barrier restoration. 
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Figure 4.5 Effect of eNOS inhibition on insulin-mediated restoration of EC 
barrier function in response to thrombin-induced hyperpermeability.  HUVEC 
monolayers were exposed to thrombin (0.2 IU/ml) in the presence or absence of insulin 
(1 IU/ml) or in the presence of specific eNOS inhibitor L-NAME (100 M) plus insulin 
or vehicle (control) as indicated. Data are mean ± SEM of 5 separate experiments of 
independent cell preparations. P<0.05 versus control; #P<0.05 versus thrombin alone; 
n.s.: not significantly different from insulin plus thrombin. 
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4.6 Effect of MLCK inhibition on insulin-mediated EC barrier restoration 
It is well established that EC barrier function is regulated by balanced activity 
of two important enzymes, MLCK and MLCP. Previously, the involvement of both 
MLCK activation and RhoA/Rock-mediated MLCP inhibition in thrombin-induced EC 
barrier dysfunction has been demonstrated (Garcia et al., 1996; Dudek and Garcia, 
2001; Velasco et al., 2002). In order to understand which of these two plays role in 
insulin-mediated EC barrier restoration in response to thrombin challenge, the activity 
of these enzymes was inhibited by using specific pharmacological inhibitor. Therefore 
in the next step the role of MLCK on insulin-mediated recovery of EC barrier function 
after thrombin challenge was assessed. (ML-7 is a specific pharmacological inhibitor 
of MLCK added at optimum concentration to block MLCK activity). MLCK is a Ca2+ 
/calmodulin (CaM)-dependent kinase that functions principally to phosphorylate 
regulatory MLC at Ser19 and subsequently at Thr18 (Shen, 2010; Garcia et al., 1995; 
Goeckeler and Wysolmerski, 1995, Hixenbaugh et al., 1997; Moy et al., 2002; Verin 
et al., 1998). It is well established that inflammatory agents like thrombin causes 
activation of MLCK which leads to EC retraction and results in barrier disruption 
(Sheldon et al., 1993; Dudek and Garcia, 2001).To elucidate the role of this kinase on 
macromolecular permeability, HUVECs were exposed to thrombin (0.2 IU/ml) in the 
presence or absence of insulin (1 IU/ml) or in the presence of pharmacological inhibitor 
ML-7 (10 µM) or ML-7 plus insulin.  
As shown in Figure 4.6 pharmacological inhibition of MLCK with ML-7 could 
neither significantly attenuate the thrombin-induced hyperpermeability nor had 
significant additive effect on insulin-mediated accelerated reduction of EC barrier 
permeability, suggesting that MLCK does not play any significant role in insulin-
mediated recovery of EC barrier function. 
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Figure 4.6 Effect of inhibition of MLCK on insulin-mediated EC barrier 
restoration 
 HUVEC monolayers were exposed to thrombin (0.2 IU/ml) in the presence or 
absence of insulin (1 IU/ml) or in the presence of specific MLCK inhibitor ML-7 (10 
µM), or ML-7 plus insulin, or vehicle (control) as indicated. Data are mean ± SEM of 5 
separate experiments of independent cell preparations.*P< 0.05 versus control; #P< 
0.05 versus thrombin alone; n.s.: not significantly different from insulin plus thrombin. 
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4.7   Effect of insulin on EC contractile machinery and dynamics of RhoA/Rock 
activity 
Endothelial actin-myosin based contractile machinery is an important regulator 
of EC barrier function (Garcia et al., 1995). Since, phosphorylation state of the 
regulatory MLC precisely controls the activation of EC contractile machinery, changes 
in this biochemical parameter of endothelial contractile activation was examined. ECs 
were exposed to thrombin (0.2 IU/ml) for different time points (min) in the presence or 
absence of insulin (1 IU/ml) as indicated. MLC phosphorylation was analyzed by 
Western blot using a phospho-specific antibody directed against Ser-19/Thr-18 of 
MLC. As shown in Figure 4.7A exposure of ECs to thrombin caused a rapid rise in 
MLC phosphorylation within 2 min, reaching maximum in 5 min and remained highly 
phosphorylated for 20 min followed by a gradual decline towards baseline. In the 
presence of insulin, the thrombin-induced effect on MLC phosphorylation was 
attenuated and dephosphorylation of MLC was faster in insulin treated ECs suggesting 
that insulin is capable to antagonize thrombin-induced activation of EC contractile 
machinery. 
Since phosphorylation of MLC is also known to be mediated via RhoA/Rock 
signalling pathway in ECs (Feng et al., 1999; Velasco et al., 2002), therefore, 
activation of RhoA/Rock signalling pathway was analyzed by measuring the 
phosphorylation state of MYPT1 at Threonine 850 (Thr-850) which is directly 
phosphorylated by Rock. ECs were stimulated with thrombin (0.2 IU/ml) for indicated 
time periods in the presence or absence of insulin (1 IU/ml) and MYPT1 
phosphorylation was analyzed by Western blot. 
As shown in Figure 4.7A thrombin caused a robust increase in MYPT1 
phosphorylation as early as 2 min and remained phosphorylated on nearly same level 
until 20 min followed by gradual declined towards the base line which was evident at 
60 minutes of thrombin stimulation, however even at 60 minutes, MYPT1 
phosphorylation level remained elevated in thrombin challenged cells as compared to 
unstimulated control ECs. Insulin effect on thrombin-induced MYPT1 phosphorylation 
was rather delayed as compared to its effect on MLC phosphorylation and a significant 
effect was seen only after 30 min. 
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Figure 4.7A Effect of insulin on thrombin-induced MLC and MYPT1 
phosphorylation in HUVECs. Representative Western blots of MYPT1 and MLC 
phosphorylation. Confluent HUVEC monolayers were exposed to thrombin (0.2 IU/ml) 
in the presence or absence of insulin (Ins, 1 IU/ml) for different time periods (min) or 
insulin alone or vehicle (C, control) as indicated. MYPT1 phosphorylation at Thr850 
and MLC phosphorylation at Ser19/Thr18 was analyzed by using phospho-specific 
antibodies. GAPDH was used as loading control. Western blots are representative of 
3 different experiments of independent cell preparations. 
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In the next step the role of Rho effector, Rock; in insulin-mediated recovery of 
EC barrier function in response to thrombin challenge was examined, by measuring 
the flux of trypan blue-labelled albumin across HUVEC monolayers. ECs were 
exposed to thrombin (0.2 IU/ml) in the presence or absence of insulin (1 IU/ml) or 
preincubated (30 min) with the low concentration of Rock inhibitor Y27632 (1 µM) in 
the presence or absence of insulin. As shown in Figure 4.7B preincubation of ECs with 
Y27632 (1 µM) significantly reduced thrombin-induced hyperpermeability both in the 
presence or absence of insulin. However in the presence of insulin the additive effect 
on EC barrier recovery was observed. Interestingly the time required for the 50% 
recovery of EC permeability from the maximum increase of permeability was less in 
the presence of Rock inhibitor Y27632 (~ 25 min vs. ~ 20 min for insulin plus thrombin 
and insulin plus thrombin in the presence of Y27632, respectively). These data 
indicate that inhibition of Rock has additive effect on insulin-mediated recovery of 
failed barrier. 
 
Results 
51 
 
 
 
Figure 4.7B Effect of Rho kinase inhibition on insulin-mediated EC barrier 
restoration. HUVEC monolayers were exposed to thrombin (0.2 IU/ml) in the absence 
or presence of insulin (1 IU/ml) or preincubated with specific Rock inhibitor Y27632 (1 
µM) for 30 min or Y27632 plus insulin or vehicle (control) as indicated and albumin 
flux (permeability) across HUVEC monolayer was measured. Data are mean ± SEM 
of 5 separate experiments using independent cell preparations.*P< 0.05 versus 
control; #P<0.05 versus thrombin alone; §P<0.05 versus insulin plus thrombin 
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4.8   Effect of insulin on Rho GTPase Rac1 activation and its role in insulin-
mediated EC barrier restoration. 
Rho GTPase Rac1 is a well characterized regulator of peripheral actin 
dynamics and is required for the stability of endothelial AJs and thus stabilizes EC 
barrier integrity (Hall, 1998; Wojciak-stothard et al., 2001; Waschke et al., 2004 and 
2006). In the next step, the involvement of Rac1 in insulin-mediated restoration of EC 
barrier function was examined. 
The effect of insulin on Rac1 activity was measured by pull down assay and the 
pull downs were analyzed for the presence of activated Rac1 (Rac1-GTP) by Western 
blotting. HUVECs were exposed to thrombin (0.2 IU/ml) in the presence or absence of 
insulin (1 IU/ml) and a change in Rac1 activity was analyzed for different time periods 
(min) as indicted. As shown in Figure 4.8A exposure of ECs to thrombin resulted in a 
significant reduction in Rac1 activity. In the absence of insulin delayed activation of 
Rac1 was observed and a significant effect was seen only after 30 min. On the other 
hand, in the presence of insulin a robust activation of Rac1 within first 15 min was 
observed suggesting the potential role of insulin in Rac1 activation. 
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Figure 4.8A   Effect of insulin on Rac1 activation. Representative Western blots of 
Rac1-GTP for different time points (min) and Rac1-total as indicated. HUVEC 
monolayers were treated with thrombin (0.2 IU/ml) in the presence or absence of 
insulin (1 IU/ml) for different time periods or vehicle (control: C) as indicated. The active 
Rac1 (Rac1-GTP) was analyzed by pull down assay. Whole cell lysate was used to 
demonstrate equal loading. Data are mean ± SEM of 5 separate experiments of 
independent cell preparations. 
 
 
In the next step the role of Rac1 activation in insulin-mediated EC barrier 
restoration after thrombin-induced hyperpermeability was further confirmed by using 
the specific pharmacological Rac1 inhibitor NSC23766 (50 µM) (Gao et al., 2004). ECs 
were exposed to thrombin (0.2 IU/ml) in the presence or absence of insulin (1 IU/ml) 
or preincubated with NSC23766 for 30 min in the presence of insulin and albumin flux 
across HUVEC monolayer was analyzed. As shown in Figure 4.8B pre-incubation of 
HUVECs with NSC23766 completely abolished the recovery effect of insulin on EC 
barrier permeability further indicating that insulin-mediated restoration of EC barrier 
function is via Rac1-dependent manner. 
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Figure 4.8B Effect of Rac1 inhibition on insulin-mediated EC barrier restoration. 
HUVEC monolayers were exposed to thrombin (0.2 IU/ml) in the presence or absence 
of insulin (1 IU/ml), or specific Rac1 inhibitor NSC23766 (50 µM) plus insulin, or vehicle 
(control) as indicated and albumin flux (permeability) across HUVEC monolayer was 
measured. Data are mean ± SEM of five separate experiments of independent cell 
preparations. *P< 0.05 versus control; #P< 0.05 versus thrombin alone; §P< 0.05 
versus insulin plus thrombin. 
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4.9 Effect of insulin on ischemia-reperfusion-induced myocardial water 
contents 
Finally a series of experiments were performed in a well-established isolated 
saline perfused rat heart model (Noll et al., 1999), to further verify the EC barrier 
recovery effects of insulin in an intact coronary system. Myocardial water content was 
defined as an index for capillary leakage and tissue edema formation. To analyze this, 
isolated perfused rat hearts were exposed to ischemia for one hour followed by 30 min 
of reperfusion (Rep) and myocardial water content was determined as described in 
methods section. Under control normoxic conditions (Nor), the mean myocardial water 
content of the normoxic perfused rat hearts was 455 mL/100g dry weight after 90 min 
as shown in Figure 4.9. 
Exposure of the isolated perfused rat hearts to ischemia followed by reperfusion 
caused a significant increase in myocardial water content to 554 mL/100 g dry weight. 
To analyze whether insulin can abolish ischemia-reperfusion-induced increase in 
myocardial water contents, reperfusion medium was supplemented with 0.1 IU/ml 
insulin (a concentration only one-tenth of that used in cell culture model), during the 
first 10 min of reperfusion markedly reduced the reperfusion-induced increase in 
myocardial water content. In one set of experiments hearts were perfused with insulin 
in the presence of specific Rac1 inhibitor NSC23766 (50 µM), added 20 min before 
the start of reperfusion and during the first 10 min of reperfusion. This manoeuvre 
abolished the protective effect of insulin on reperfusion-induced increase in myocardial 
water content clearly indicating that insulin-induced barrier recovery is via Rac1 
dependent pathway. 
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Figure 4.9 Effect of insulin on myocardial water content of the isolated saline 
perfused rat hearts after ischemia-reperfusion. Hearts were exposed for 60 min to 
ischemia followed by 30 min of reperfusion (Rep) or 90 min of normoxia (Nor). Insulin 
(Ins; 0.1 IU/ml) was added at the start of reperfusion during the first 10 min. In one set 
of experiments hearts were perfused in the presence of insulin and Rac1 inhibitor 
NSC23766 (50 µM), which was added 20 min before the start of reperfusion and during 
the first 10 min of reperfusion. Data are mean ± SEM of 5 separate experiments with 
independent organ preparations. *P<0.05 versus Nor; #P<0.05 versus Rep.  
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5. DISCUSSION 
 
5.1   Main Findings 
The precise regulation of semi-permeable barrier function of vascular 
endothelium lining intima of blood vessels is very important for the exchange of water, 
small solutes, ions and macromolecules (Michel and curry, 1999; Mehta and Malik, 
2006). Disruption of this EC barrier function is often the underlying cause of vascular 
leakage and life threatening edema formation during pathophysiological conditions like 
inflammation and ischemia-reperfusion injury (Bazzoni, 2006; Yuan et al., 2007; 
Kumar et al., 2009). 
 It is well-established that disruption of endothelial AJs and activation of the EC 
contractile machinery are the key steps towards opening of intercellular gaps and 
finally leading to EC barrier failure under conditions of hyperpermeability which is a 
characteristic response to inflammatory agents such as thrombin (Gündüz et al., 2003; 
Birukova et al., 2004; Aslam et al., 2012 and 2014). Inflammatory agent thrombin 
disrupts EC barrier integrity, followed by a slow recovery of the EC barrier function 
within 2 hrs. 
The mechanisms regulating recovery of EC barrier function are essential to 
regain vascular integrity and successful resolution of edema. However; the precise 
molecular mechanisms involved in this recovery/restoration of EC barrier function 
subsequent to EC barrier disruption have not yet been well understood. Comparatively 
little is known about the maneuvers that can enhance/facilitate the restoration of 
compromised EC barrier function. 
It is well known that intensive insulin therapy confers vasoprotective effects and 
reduces major cardiovascular complications in diabetics, because of its anti-
inflammatory and anti-atherosclerotic effects (Nathan et al., 2005; Langouche et al., 
2005; Kim et al., 2006; Dandona et al., 2009). Hyperpermeability of vasculature is the 
hallmark of aforementioned disease states.  
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The present study was carried out to address the potential role of insulin in the 
recovery of EC barrier function in response to thrombin-induced hyperpermeability. 
Special focus was laid on the dynamics of endothelial contractile activation, 
disassembly and re-assembly of AJs and dynamic activities and involvement of Rac1. 
Our data demonstrate that insulin accelerates recovery of EC barrier function in 
response to thrombin challenge in a well-established in vitro model of HUVECs. 
Moreover, it also abolished the ischemia-reperfusion-induced vascular leakage and 
edema formation in the intact isolated-perfused rat hearts. 
 
The main and novel findings of the present study are as follows  
1. Insulin enhances the recovery of EC barrier function in response to thrombin-
induced EC hyperpermeability in a receptor-dependent manner. 
2. Insulin fastens re-establishment of VE-cadherin dependent AJs after thrombin 
challenge. 
3. Insulin-induced recovery of EC barrier function is via PI3K/Akt-dependent 
pathway. 
4. eNOS/NO signaling plays no role in insulin-mediated recovery of EC barrier 
function. 
5. Inhibition of MLCK does not play any role in insulin-mediated restoration of EC 
barrier function. 
6. Insulin partly antagonized thrombin-induced increase in MLC and MYPT1 
phosphorylation. 
7. Insulin-mediated restoration of EC barrier function is via Rho GTPase Rac1 
activation. 
8. Insulin abolished the ischemia-reperfusion-induced increase in myocardial 
water content via Rac1 activation. 
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5.2 Insulin accelerates the recovery of EC barrier function in response to 
thrombin-induced hyperpermeability in a receptor-dependent manner 
Consistent with previous studies the data of the present study show that 
inflammatory mediator thrombin disrupted the permeability of HUVEC monolayer 
followed by slow recovery towards basal permeability level. Treatment with insulin 
significantly abolishes thrombin effects from permeability-increasing to a barrier-
recovery response in ECs under study. Remarkably, the time required for the half 
maximal recovery of monolayer permeability was significantly less in the presence of 
insulin suggesting that insulin accelerated EC barrier restoration. Like other many cell 
types ECs also express insulin receptors (Zeng et al., 2000; Nitert et al., 2005). 
Inhibition of insulin receptors abolished the EC barrier recovery effect of insulin which 
demonstrating barrier restoration effect of insulin is receptor-mediated which is in line 
with our previous report (Gündüz et al., 2010) showing that insulin stabilized 
microvascular EC barrier function in a receptor-dependent manner. 
 
5.3   Insulin induces fast reassembly of AJs after thrombin challenge. 
Endothelial actin cytoskeleton anchored AJs composed of VE-cadherin are one 
of the key regulators of EC barrier function. Reassembly of AJs precedes the recovery 
of vascular endothelial barrier integrity and is integral for the maintenance of normal 
state of EC barrier function (Bazzoni and Dejana, 2004; Wallez and Huber, 2008). 
Thrombin induces EC hyperpermeability via disassembly of AJs (Garcia et al., 1986) 
leading to drastic disappearance of VE-cadherin from cell-cell junctions, and 
intercellular gap formation. This is followed by slow reappearance of VE-cadherin at 
cell-cell junctions. The changes in VE-cadherin localization at cell-cell junctions are 
well coordinated with the dynamics of increase and decrease in albumin permeability. 
Insulin attenuated this thrombin effect on endothelial AJs and promoted fast re-
appearance of VE-cadherin at cell-cell junctions thereby strengthened AJs. Insulin-
induced fast re-establishment of AJs is mediated via translocation of VE-cadherin to 
cell-cell junctions.  
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5.4 Insulin-induced EC barrier restoration is via PI3K/Akt-dependent pathway 
A classical signaling pathway activated by insulin is PI3K/Akt signaling which 
mediates most of insulin effects in variety of cell types including ECs (Gündüz et al., 
2010; Lee and Ragolia, 2006; Zeng et al., 2000; Hermann et al., 2000). The current 
study further establishes that the insulin-dependent activation of the PI3K/Akt signaling 
pathway is required for insulin-mediated EC barrier restoration process. The activation 
of the PI3K/Akt signaling pathway by insulin in ECs under study is demonstrated by 
Akt phosphorylation. Insulin-induced a robust increase in Akt phosphorylation and Akt 
phosphorylation is sustained over the maximum indicated periods of time. Accordingly, 
inhibition of PI3K completely abolished the insulin-mediated recovery of EC barrier 
function in response to thrombin-induced EC hyperpermeability, further supporting 
that insulin-mediated recovery of EC barrier function is via activation of PI3K/Akt 
pathway. 
 
5.5 Effect of eNOS inhibition on insulin-mediated EC barrier recovery 
In ECs insulin induces NO production via PI3K/Akt-dependent activation of 
eNOS (Zeng et al., 2000; Federici et al., 2002; Montagnani et al., 2001 and 2002 ;) 
which has been shown to stabilize in part microvascular EC barrier function (Gündüz 
et al., 2010). Therefore, the effect of L-NAME mediated eNOS inhibition on the EC 
barrier recovery effect of insulin in response to thrombin challenge was investigated.  
In contrast to our previous report (Gündüz et al., 2010) on rat coronary 
microvascular ECs, inhibition of eNOS in HUVECs was unable to abrogate EC barrier 
stabilizing effects of insulin. This difference may be due to different vascular beds 
investigated in these studies or even may be due to species differences. 
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5.6 Role of endothelial contractile machinery. 
Actin-myosin based EC contractile machinery is one of the important 
determinants of EC barrier function (Garcia et al., 1995). MLC is a regulatory 
component of the EC contractile machinery and its phosphorylation plays a pivotal role 
in controlling the activation of EC contractile machinery, this parameter of contractile 
activation was also explored in this study 
MLC phosphorylation is regulated by antagonistic but balanced activities of 
MLCP (Härtel et al., 2007; Knapp et al., 1999; Verin et al., 1995 and 2000) and MLCK 
(Verin et al., 1998; Lazar and Garcia., 1999). It is well established that thrombin causes 
inhibition of MLCP which results in EC contraction and finally leading to EC barrier 
disruption (Sheldon et al., 1993; Hixenbaugh et al., 1997; Verin et al., 1998; Goeckeler 
and Wysolmerski, 2005). The results of the present study demonstrate that thrombin 
caused a rapid rise in MLC phosphorylation. Insulin effectively attenuated this effect 
of thrombin in ECs under study and MLC dephosphorylation was faster in the presence 
of insulin, suggesting that insulin is capable to antagonize thrombin-induced activation 
of EC contractile machinery and may accelerate restoration of thrombin-induced failed 
barrier.  
Inhibition of MLCK with ML-7 (a specific inhibitor of MLCK) could neither 
significantly attenuate the thrombin-induced EC hyperpermeability nor have any 
additive effect on insulin mediated recovery of EC barrier function suggesting that 
MLCK does not play role in insulin-mediated EC barrier restoration process. A similar 
report recently in ECs showed that, ML-7 could neither attenuate the thrombin-induced 
EC hyperpermeability nor augment the EC barrier recovery (Aslam et al., 2014). Even 
though previous reports indicate that ML-7 antagonized hypoxia/reoxygenation 
induced EC hyperpermeability (Aslam et al., 2013). 
However, in contrast to the present study, Moy et al. showed that ML-7 blocked 
thrombin-induced hyperpermeability in HUVECs (Moy et al., 2002). The discordance 
between Moy group and present study is possibly due to high concentrations of drugs 
used by them. They used thrombin at a very high concentration (7 IU/ml) which is 35-
fold higher compared to use in the present study and ML-7 was used at concentration 
of 100 µM (10-fold higher used in the present study). At high concentration ML-7 may 
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also block PKC (Odani et al., 2003) and these inhibitory effects presented by Moy 
group are perhaps due to inhibition of PKC and not due to MLCK. 
It is well-demonstrated that RhoA/Rock signaling pathway plays an important 
role in regulating EC barrier function and pharmacological inhibition of Rock with 
specific cell permeant inhibitor (Y27632, 10 µM) not only antagonized thrombin-
induced contractile activation (Aslam et al., 2010) but also reduced thrombin-induced 
hyperpermeability (Aslam et al., 2014). Therefore, in the context of the study in the 
next step the effect of inhibition of RhoA/Rock signaling in insulin mediated EC barrier 
restoration was observed. Indeed, inhibition of Rock with 10 fold low concentration of 
Y27632 (1 µM) restores HUVEC monolayer permeability in both insulin and thrombin 
stimulated conditions. However, inhibition of the RhoA/Rock pathway in the presence 
of insulin has additive effect on recovery of failed barrier. This suggests the existence 
of Rock-independent pathway mediating EC barrier restoration. 
A second mechanism of MLC phosphorylation is via activation of RhoA/Rock 
signaling pathway. The endothelial MLCP holoenzyme is a heterotrimeric enzyme 
composed of a regulatory subunit, (MYPT1; an endogenous direct substrate of Rock) 
(Aslam et al., 2010) and a catalytic subunit (PP1). RhoA/Rock signaling pathway is 
one of the most important intracellular phosphorylation trigger of MYPT1 at its 
inhibitory sites (Kimura et al., 1996). MYPT1 phosphorylation at Thr-850 led to 
inhibition of MLCP, activation of EC contractile machinery and thereby barrier 
malfunction (Feng et al., 1999; Velasco et al., 2002; Birukova et al., 2004). Therefore, 
in the context of the study the question was examined whether insulin can counteract 
thrombin-induced MYPT1 phosphorylation. The data of the present study demonstrate 
that thrombin caused a robust increase in MYPT1 phosphorylation which is in 
consistent with the assumption that thrombin-induced activation of contractile 
machinery is dependent on inhibition of MLCP. Insulin decreases thrombin-induced 
MYPT1 phosphorylation. Insulin effect on MYPT1 dephosphorylation is rather delayed 
as compared to its effect on MLC dephosphorylation. The fast dephosphorylation of 
MLC but delayed dephosphorylation of MYPT1 in the presence of insulin suggesting 
that in addition to MLCP activation, other signaling mechanisms are involved in the 
control of contractile inactivation and EC barrier restoration and needs further 
investigations. 
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5.7 Effect of Insulin on Rho GTPase, Rac1 activity and its role in insulin-
mediated EC barrier recovery. 
Rac1, a member of Rho family of GTPases, have been well recognized as an 
important regulators of endothelial actin cytoskeleton dynamics and stimulates the 
formation of AJs and that it plays a critical role for the maintenance of EC barrier 
integrity (Wojciak-stothard et al., 2001 and 2006; Waschke et al., 2004 and 2006; 
Vandenbroucke et al., 2008; Gündüz et al., 2010; Aslam et al., 2011, 2013 and 2014; 
Schnittler et al., 2014). Therefore in the next step the dynamics of changes in the Rac1 
activation were analyzed. 
The results of the present study clearly show that insulin activates Rac1 in ECs 
under study and protects against thrombin-induced Rac1 inactivation. Even though 
the precise mechanism of Rac1 activation is beyond the scope of this study. Rac1 
activation could be mediated via activation of the Rac1-specific guanine nucleotide 
exchange factors (GEFs) Tiam1 and TrioN, Insulin can activate TrioN and Tiam1, the 
GEFs of Rac1, because pharmacological inhibition of these Rac1-GEFs with the 
specific inhibitor, NSC23766, abolished the EC barrier recovery effect of insulin on 
macromolecular permeability, indicating an essential role of Rac1 in insulin-mediated 
restoration of EC barrier function. Nevertheless, these findings strongly emphasize the 
important and decisive role of Rac1 in insulin-mediated recovery of EC barrier function. 
 
5.8 Insulin reduces ischemia-reperfusion-induced increased myocardial 
water content via Rac1. 
Ischemia-reperfusion disrupts the barrier function of vascular endothelium, 
leading to myocardial edema formation which jeopardizes the functional recovery of 
the heart during reperfusion (Garcia and Oliveras, 1993; Rubboli et al., 1994; Mehlhorn 
et al., 2001; Dongaonka et al., 2012). The barrier recovery effect of insulin against 
ischemia-reperfusion-induced endothelial barrier failure was also further supported by 
our data obtained in the intact coronary system of the isolated saline perfused rat heat 
model (Noll et .al., 1999). Insulin, when applied at the onset of reperfusion for only a 
short period of time strongly reduced the reperfusion-induced increase in myocardial 
water content. These data depict that insulin plays a beneficial role in the stabilization 
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of vascular barrier permeability in the intact coronary system, indicating that insulin 
application during the reperfusion can protect the heart against reperfusion-induced 
injury and an imminent life threatening edema. However in the intact coronary system 
this protective effect of insulin was abolished if the heart was perfused in the presence 
of insulin with specific Rac1 inhibitor NSC23766, clearly indicating that insulin-
mediated EC barrier protection/restoration is via Rac1 dependent. 
 
5.9 Conclusion  
Collectively, the results of the present study conclude that insulin accelerates 
restoration of EC barrier function in response to thrombin-induced hyperpermeability 
of HUVEC monolayers via enhancement of cell-cell adhesions and inactivation of the 
EC contractile machinery. Moreover, insulin also abolished reperfusion-induced 
vascular leakage in isolated-saline perfused rat hearts. These EC barrier restoration 
effects of insulin are mediated via PI3K/Akt and Rho GTPase, Rac1 activation which 
plays a decisive role in insulin-mediated EC barrier restoration in cultured EC 
monolayers as well as in intact coronary system of isolated-saline perfused rat heart. 
Furthermore thrombin-induced activation of RhoA/Rock is an important trigger in 
inducing EC barrier disruption, inhibition of RhoA/Rock signaling enhances the rate of 
endothelial barrier recovery in the presence of insulin. Importantly, inhibition of eNOS 
and MLCK do not play any role in insulin-mediated endothelial barrier recovery. Taken 
together, these findings may warrant further evaluation of the therapeutic potential of 
insulin on accelerated recovery of failed EC barrier function and reduction of vascular 
leakage under inflammatory situations and beyond. 
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7. SUMMARY 
 
The vascular endothelium forms a semi-permeable barrier between blood and 
interstitium controlling the exchange of water, small solutes, ions, macromolecules and 
blood cells across the vessel wall. Loss of EC barrier function results in leakage of 
blood components to interstitium and finally life threatening edema formation during 
pathophysiological conditions like inflammation and ischemia-reperfusion. Thus, 
restoration of EC barrier function is important to regain vascular barrier integrity and 
to prevent edema formation. However, little is known about the mediators and 
mechanisms involved in the recovery of compromised EC barrier function. 
The maintenance of EC barrier integrity is highly dependent on the VE-
cadherin-based AJs and actomyosin-based EC contractile machinery. It is now well-
established that the disruption of endothelial AJs and activation of EC contractile 
machinery are the key steps leading towards EC barrier failure under hyper-permeable 
conditions, a typical EC response to inflammatory mediators such as thrombin. 
Insulin is an essential hormone and a key regulator of metabolism. Additionally, 
it also confers protective effects on the cardiovascular system. Inflammatory mediators 
like thrombin disrupts EC barrier function, which is recovered slowly. Here, the 
hypothesis was addressed whether insulin can mediate a faster restoration of EC 
barrier function and the underlying signaling mechanism by which insulin recovers the 
EC barrier function was elucidated.  
 Our data demonstrate that thrombin-induced hyperpermeability of HUVEC 
monolayers has accelerated recovery in the presence of insulin in a concentration-
dependent manner with maximal effect at 1 IU/ml of insulin concentration. This barrier 
restoration effect of insulin in response to thrombin-induced hyperpermeability was 
blocked by a specific insulin receptor antagonist. Insulin also abolished reperfusion-
induced vascular leakage in isolated-saline perfused rat hearts. Insulin-induced a rapid 
increase in Akt phosphorylation in HUVECs. Accordingly, inhibition of PI3K with 
wortmannin completely abolished the insulin-mediated EC barrier restoration, further 
supporting that the EC barrier recovery function of Insulin is via activation of PI3K/Akt 
pathway. However, MLCK and eNOS/NO signaling pathways are not involved in 
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insulin-mediated recovery of EC barrier function. Insulin attenuated thrombin-induced 
increase in MLC and MYPT1 phosphorylation and also fastens the re-establishment 
of VE-cadherin dependent endothelial AJs in response to thrombin challenge 
indicating a contractile inactivation and stabilization of cell-cell adhesion structures. 
Remarkably, inhibition of Rock has additive effect on insulin-mediated accelerated 
restoration of failed barrier. Insulin activated Rho GTPase Rac1 and pharmacological 
inhibition of Rac1 activity by using a specific inhibitor (NSC23766) abrogated the EC 
barrier recovery effect of insulin on  cultured EC monolayers, as well as on reperfusion-
induced vascular leakage in intact  isolated-saline perfused rat heart, suggesting a 
Rac1-dependent phenomenon. 
In conclusion, insulin accelerates restoration of EC barrier function in response 
to thrombin-induced EC barrier disruption via enhancement of cell-cell adhesion 
structures and inactivation of the EC contractile machinery. Insulin also abolished 
reperfusion-induced vascular leakage in isolated saline perfused rat hearts. These EC 
barrier restoration effects of insulin are mediated via PI3K/Akt and Rho GTPase-Rac1 
activation which plays a decisive role in insulin-mediated recovery of EC barrier 
function both in HUVEC monolayers and in isolated perfused rat hearts. 
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8. ZUSAMMENFASSUNG  
 
 Das vaskuläre Endothel stellt eine semipermeable Barriere zwischen Blut und 
Interstitium dar. Es kontrolliert den Austausch von Wasser, gelösten Substanzen, 
Ionen, Makromolekülen und Blutzellen durch die Gefäßwand. Unter verschiedenen 
pathophysiologischen Bedingungen, beispielsweise bei Entzündung und Ischämie-
Reperfusion, kann der Verlust dieser Schrankenfunktion zu einer Leckage der 
Blutkomponenten ins Interstitium und damit zu einem lebensbedrohlichen Ödem 
führen. Die Wiederherstellung der endothelialen Schrankenfunktion ist wichtig, um die 
vaskuläre Integrität zu erhalten und die Entwicklung von Ödemen zu verhindern. 
Allerdings ist bisher wenig über Mediatoren und Mechanismen bekannt, welche in die 
Erholung der Barrierenfunktion involviert sind. Der Erhalt der endothelialen 
Barrierenintegrität hängt einerseits von interzellulären Adhäsionsstrukturen (AJ) ab, 
die auf VE-Cadherin basieren, andererseits vom endothelialen kontraktilen Apparat, 
der auf Actin-Myosin basiert. Es ist bekannt, dass eine Zerstörung der endothelialen 
AJs und eine Aktivierung der endothelialen kontraktilen Elemente die 
Schlüsselschritte sind, die zum Verlust der Schrankenfunktion führen.  
Das essentielle Hormon Insulin ist ein wichtiger Stoffwechselregulator und hat 
zudem protektive Effekte im kardiovaskulären System. Entzündungsmediatoren wie 
Thrombin stören die endotheliale Schrankenfunktion, die sich dann nur langsam 
erholt. In dieser Studie wurde die Hypothese geprüft, ob Insulin eine beschleunigte 
Regeneration der endothelialen Barrierefunktion vermitteln kann und welche 
insulinvermittelten Signalwege hier zugrunde liegen. 
Unsere Ergebnisse zeigen, dass sich in Anwesenheit von Insulin die Thrombin-
induzierte Hyperpermeabilität von HUVEC-Monolayern schneller regeneriert. Dieser 
Effekt ist konzentrationsabhängig. Die durch Insulin induzierte Erholung kann durch 
den spezifischen Insulinrezeptor-Inhibitor S961 blockiert werden. Des Weiteren kann 
durch Insulin die Reperfusions-induzierte vaskuläre Leckage in isolierten, salin 
perfundierten Rattenherzen aufgehoben werden. Insulin löst einen schnellen Anstieg 
der Akt-Phosphorylierung in HUVEC aus. Die Wiederherstellung der endothelialen 
Barrierefunktion ist hierbei abhängig vom PI3K/Akt-Signalweg. MLCK- und eNOS/NO-
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Signalwege sind nicht involviert. Insulin hemmt den Thrombin-induzierten Anstieg von 
MLC- und MYPT1-Phosporylierung und beschleunigt die Wiederherstellung der VE-
Cadherin-abhängigen endothelialen AJs. Dies weist auf eine Inaktivierung des 
kontraktilen Apparates und auf eine Stabilisierung von Zell-Zell-Adhäsionsstrukturen 
hin. Eine ROCK-Hemmung hat einen additiven protektiven Effekt. Insulin aktiviert die 
Rho GTPase Rac1. Die pharmakologische Hemmung von Rac1 mithilfe spezifischer 
Inhibitoren (NSC23766) hebt bei Reperfusions-induzierter vaskulärer Leckage die 
Erholung der endothelialen Schrankenfunktion in isolierten EC Monoschichten von 
isolierten, salin perfundierten Rattenherzen durch Insulin auf. Dieser Effekt ist ein 
Hinweis für einen Rac-1 abhängigen Mechanismus. 
Schlussfolgernd ist zu konstatieren, dass Insulin die Erholung der EC 
Schrankenfunktion nach Thrombin-induziertem Schaden durch eine Verstärkung der 
Zell-Zell-Adhäsion und eine Inaktivierung des kontraktilen Apparates beschleunigt. 
Insulin hemmt zudem die vaskuläre Leckage von isolierten, salin perfundierten 
Rattenherzen. Diese protektiven Effekte werden über einen PI3K/Akt- und Rho 
GTPase-Rac1 Signalweg vermittelt und spielen eine entscheidende Rolle bei der 
insulinvermittelten Erholung der endothelialen Schrankenfunktion sowohl in HUVEC 
als auch in isolierten, salin perfundierten Rattenherzen. 
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